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ABSTRACT
Individuals with serious mental illness (SMI) are disproportionately impacted by
preventable physical health conditions, which put them at risk for premature mortality. Integrated
primary and behavioral health care (PBHC) programs have demonstrated promise in treating
comorbid physical and mental health conditions, common to individuals diagnosed with SMI.
The current study focused on individuals with thought disorders (i.e., schizophrenia,
schizoaffective disorder, and brief psychotic disorder), as those diagnosed are more likely to be
retained in care. Treatment retention is especially important, as adherence slows down the
progression of psychiatric symptoms and physical health diseases. Extant research has focused
on evaluation of the efficacy of PBHC programs. This exploratory secondary analysis
contributes to the growing knowledge base of research on integrated PBHC programs and the
clients who receive these services by examining relevant correlates (i.e., sociodemographic,
health, health-risk, and treatment-related characteristics) of health and psychosocial
improvements among 311 individuals with thought disorders receiving co-located services in 3
community mental health (CMH) settings. Variables significantly associated with improvements
in health and psychosocial characteristics included employment status, disability status, living
situation, access to reliable transportation, and clinic site, suggesting that social determinants are
relevant for this population. Directions for future research and implications for social work
practice and education are discussed.
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CHAPTER 1: INTRODUCTION
Serious mental illness (SMI) is a major social welfare issue of concern for social workers
employed in diverse health and mental health settings. The current study examined correlates of
health and psychosocial improvements among individuals with thought disorders (i.e.,
schizophrenia, schizoaffective disorder, brief psychotic disorder) receiving integrated primary
and behavioral health care (PBHC) services in community mental health (CMH) settings. This
chapter provides an overview of the pervasiveness of SMI and the health disparities that this
population faces, with a special focus on thought disorders. Additionally, the biopsychosocial
(BPS) model is introduced as a relevant theoretical framework for conceptualizing the topic of
study. Finally, the study’s significance to the field of social work is discussed.
Problem Statement
It is well known that individuals with SMI are disproportionately affected by physical
health conditions, which often lead to the development of serious comorbidities and premature
mortality (Parks, Svendsen, Singer, & Foti, 2006). Efforts have been made to eliminate existing
health disparities through federally-supported grants (Scharf et al., 2013), and evaluative studies
(Druss et al., 2010; Putz et al., 2015) have demonstrated the effectiveness of government-funded
PBHC programs in CMH settings. However, prior to this analysis, no study to date had examined
potential correlates (i.e., sociodemographic, health, health-risk, and treatment-related
characteristics) of health and psychosocial improvements among individuals with thought
disorders receiving integrated services in CMH settings. New knowledge about potential
predictors of improvement may help guide social workers in direct practice and policy-practice
roles with regard to developing resources and systematic efforts to strengthen services to this
vulnerable subpopulation of clients with SMI.
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Importance of the Problem
SMI can be very debilitating for affected individuals, as those diagnosed experience a
variety of complex psychiatric symptoms (American Psychiatric Association [APA], 2013),
stigma (Stuart & Arboleda-Flórez, 2012), and high rates of comorbid physical health conditions
(Parks et al., 2006). This crisis extends beyond the individual level, impacting family members
of those affected and the public at large (Kennedy, 2013). Loved ones of persons with SMI often
face some level of stigma (Sartorius, 2002) and are often left with the hefty financial costs of
treatment (Kennedy, 2013). Further, in terms of public health resources, communities are
impacted by the frequent emergency room visits, hospitalizations, and incarcerations of
individuals with SMI (Kennedy, 2013).
Scope of the Problem
SMI, defined by the Substance Abuse and Mental Health Services Administration
(SAMHSA, 2016) as any mental or behavioral disorder that causes significant impairment in an
individual’s day-to-day living, includes both mood disorders (e.g., major depression, bipolar
disorder) and thought disorders. Approximately 4% of adults in the United States (an estimated
9.8 million) have SMI (SAMHSA, 2016).
The extent research shows that persons diagnosed with SMI live, on average, 25 years
less than the general population (Parks et al., 2006). According to Parks et al. (2006), 60% of
premature deaths among those specifically diagnosed with thought disorders can be attributed to
preventable physical health conditions (e.g., cardiovascular disease, pulmonary disease,
infectious disease). Further, most of the risk factors that contribute to these diseases (e.g.,
smoking, alcohol consumption, drug use, poor nutrition, sedentary lifestyle) are modifiable
(Parks et al., 2006).
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Despite the high prevalence rates of physical health conditions among individuals with
SMI, evidence from a variety of sources shows that they are less likely to visit physicians for
routine medical care than the general population (Druss & Walker, 2011). Further, studies
conducted in the last decade or so show that those who do have some source of routine medical
care often receive subpar services (Miller, Druss, Dombrowski, & Rosenheck, 2003). As
individuals with SMI are more likely to seek health care services through CMH centers, these
agencies are the ideal locations to provide coordinated, integrated PBHC services (Druss et al.,
2010). The shift toward integrated care is relatively new (Scharf et al., 2013), so little research
evaluating program effectiveness has been published. However, two studies (Druss et al., 2010;
Putz et al., 2015) examining the effectiveness of integrated programs in CMH settings have
demonstrated promising results with regard to improved health outcomes. The next step for
researchers is to examine relevant correlates of health and psychosocial improvements, and this
study precisely sought to identify empirically relevant predictors of improvement among clients
with thought disorders receiving integrated PBHC services.
This exploratory secondary analysis used existing data collected at baseline and follow up
from clients with thought disorders enrolled in integrated PBHC programs at three CMH centers.
The current study sought to determine which sociodemographic, health, health-risk, and
treatment-related characteristics were associated with health and psychosocial improvements.
Theoretical Significance
The current study is rooted in BPS theory. George L. Engel, a psychiatrist, first
introduced the BPS model in 1977. This theory claims that an individual’s wellbeing is impacted
by biological, psychological, and social factors (Engel, 1977); further, BPS theory asserts that a
holistic approach addressing all three of the aforementioned dimensions is necessary when
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treating individuals (Engel, 1977). As people with SMI experience numerous psychiatric
symptoms and comorbid physical health conditions, which are often created or exacerbated by
environmental factors (Druss & Walker, 2011), an understanding of the multiple factors and their
interrelationships is critical for conceptualizing this descriptive study.
Contributions to the Field of Social Work
According to the National Association of Social Workers’ (NASW, 2017) Code of
Ethics, social workers have an ethical responsibility to “pursue social change, particularly with
and on behalf of vulnerable and oppressed individuals and groups of people.” Individuals with
SMI are still among the most stigmatized groups in society (Stuart & Arboleda-Flórez, 2012),
and in addition to suffering from a variety of complex psychiatric symptoms (APA, 2013),
people with SMI are disproportionately affected by comorbid physical health conditions (Parks
et al., 2006). Individuals with SMI are at increased risk for experiencing stigma, chronic
diseases, and premature mortality (Parks et al., 2006); thus, social workers must focus their
efforts towards eliminating these disparities.
According to NASW (n.d.), social workers account for 60% of the mental health
workforce. As such, they are in the ideal position to advocate for individuals with SMI. As
systems of care move toward greater integration (Gerrity, Zoller, Pinson, Pettinari, & King,
2014), understanding the characteristics associated with improvements in health and
psychosocial outcomes among CMH clients with SMI enrolled in integrated PBHC programs is
timely. The current study focused specifically on clients with thought disorders, as they are less
understood and more likely to receive social rejection and less compassion (Angermeyer &
Deitrich, 2006). In addition, recent investigations show that CMH clients with thought disorders
are more likely than those with mood disorders to be retained in care (Thomas, 2017; Lemieux,
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Thomas, Newransky, Khalifa, & Hebert, 2017). This is important because treatment retention is
associated with improved health and psychosocial outcomes for this particular population (Druss
& Walker, 2011; Adair et al., 2005). Results generated from this study may help social work and
other health practitioners identify potential predictors (i.e., sociodemographic, health, health-risk,
and treatment-related characteristics) that indicate areas of risk and resilience regarding health
and psychosocial improvements among individuals with thought disorders. Such knowledge may
guide social workers engaged in direct practice and policy-practice roles to develop and test
relevant interventions, including recovery support services that target health- and psychosocialrelated risks and resiliencies.
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CHAPTER 2: REVIEW OF THE LITERATURE
This chapter reviews existing literature on the pervasiveness of SMI and the increased
physical health risks among this population. The analysis has a special focus on thought
disorders; thus, discussion focuses on diagnostic criteria, prevalence rates, best practices, risks
for deterioration, information on mental health stigma, and statistics on physical and mental
health comorbidity. Models of integrated PBHC have demonstrated promise in treating comorbid
mental and physical health conditions, and a summary of major evaluation findings and
implications will be provided. Finally, treatment retention and disengagement will be reviewed.
An Overview of Serious Mental Illnesses and Thought Disorders
According to SAMHSA (2016), SMI can be defined as any mental or behavioral disorder
that causes significant impairment in one’s functioning and one’s ability to complete major
activities. Approximately 4% of adults in the United States (an estimated 9.8 million) have SMI
(SAMHSA, 2016). Of the portion of adults with SMI, roughly 5% are female and about 3.1% are
male (SAMHSA, 2015). Whites have higher prevalence rates (4.4%) than Hispanic/Latinos
(3.5%), Blacks (3.1%), and Asians (2.4%; SAMHSA, 2015). Individuals without health
insurance are more likely to be diagnosed with SMI than individuals with health coverage
(SAMHSA, 2015). Additionally, individuals who live below the federal poverty level are almost
2 times more likely to have SMI than those who live above the federal poverty level (SAMHSA,
2015).
SMI includes both mood disorders (e.g., major depression, bipolar disorder) and thought
disorders (i.e., schizophrenia, schizoaffective disorder, brief psychotic disorder). This analysis
will focus on different aspects of thought disorders.
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Schizophrenia
Prevalence and Incidence. According to the World Health Organization (WHO, 2016),
approximately 21 million people are affected by schizophrenia worldwide. The American
Psychiatric Association (APA, 2013) stated that prevalence rates range from 0.3% to 0.7%, with
some variation across countries. The median incidence of schizophrenia is roughly 0.20 per
1,000 persons annually (Messias, Chen, & Eaton, 2007).
Symptoms and Primary Diagnostic Criteria. In order for a diagnosis of schizophrenia
to be established, there must be an active phase, that is, a period in which at least two of the
following symptom categories are present: delusions, hallucinations, disorganized speech,
behavioral disturbances of either disorganization or catatonia, and negative symptoms (APA,
2013). Furthermore, at least one of the two required symptom categories are delusions,
hallucinations, or disorganized speech. Negative symptoms include diminished emotional
expression, avolition (i.e., decreased motivation and interests), alogia (i.e., poverty of speech),
anhedonia, and asociality (APA, 2013).
Additional criteria must be met for a diagnosis of schizophrenia. Symptoms must last at
least 6 months, a portion of which must include an active phase of at least 1 month’s duration,
but it can be shorter if treatment reduces the length of the symptomatic period (APA, 2013).
Active-phase symptoms must not appear solely in the context of a mood episode. Symptoms of
the prodromal-phase (i.e., a period preceding or leading up to an active phase) or the residualphase (i.e., a period following an active phase) must include negative symptoms or reduced
forms of active-phase symptoms. Symptoms cannot be the result of a substance or some other
health condition. Finally, the disorder must interfere with functioning in work, relationships, or
activities of daily living (APA, 2013).
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Gender and Race Considerations. Men are more likely than women to receive a
diagnosis of schizophrenia (WHO, 2016), and men with the disorder usually experience their
first psychotic episode at an earlier age than women with the disorder (Andreasen & Black,
2006). Overall, women tend to experience less severe functional deficits prior to the onset of the
illness, as well as experience fewer symptoms as the disorder progresses (Canuso & Pandina,
2007).
Although White individuals have a higher prevalence of SMI than other races, Black
individuals are disproportionately diagnosed with schizophrenia, with race emerging as the most
influential factor when diagnosing schizophrenia in a hospital setting (Barnes, 2013). After
controlling for age, gender, education, and number of prior hospitalizations, Barnes (2013) found
that Black clients were twice as likely as White clients to be diagnosed with schizophrenia.
Another earlier study by Barnes (2008) showed that White clients were more likely than Black
clients to be diagnosed with a mood disorder than with schizophrenia. As noted by Barnes
(2008), misdiagnosis of schizophrenia can lead to individuals being prescribed medications that
are inappropriate for their actual diagnoses, which can expose them to unnecessary side effects
and other health problems.
Racial disparities also emerge in the pharmacological treatment of schizophrenia. For
example, Kreyenbuhl, Zito, Buchanan, Soeken, and Lehman (2003) analyzed data collected with
the Schizophrenia Patient Outcome Research Team (PORT) and showed that Black persons with
schizophrenia were 3 times more likely than White persons with schizophrenia to receive longacting injectable antipsychotics. Results also showed that Black individuals were 76% less likely
than White individuals to receive the newer atypical antipsychotic medications, even after
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controlling for age, gender, education, and number of prior hospitalizations (Kreyenbuhl et al.,
2003).
Best Practices and Treatment Considerations. According to Chien and Yip (2013), the
use of antipsychotic medication continues to be the primary form of treatment for individuals
with schizophrenia. Additionally, recent meta-analyses suggest that psychosocial interventions in
combination with medications are effective in reducing acute psychotic symptoms, slowing
illness progression, and maintaining remission (Chien & Yip, 2013).
Keating et al. (2017) completed a systematic review of existing clinical practice
guidelines on treating positive symptoms in first-episode schizophrenia. A total of 3,299 articles
containing treatment recommendations were retrieved from PubMed and EMBASE databases
(Keating et al., 2017). After comparing clinical practice guideline content from included studies,
Keating et al. (2017) compiled a list of recommendations. Overwhelmingly, clinical practice
guidelines concurred/showed that typical and atypical antipsychotics were equally effective in
treating first-episode psychotic symptoms (Keating et al., 2017). Results also indicated that the
benefits of an antipsychotic medication regimen are generally evident within the first 2 weeks;
however, 4 weeks is the generally recommended duration for determining the benefit of a
particular antipsychotic regimen (Keating et al., 2017).
Recently, there has been much debate over the potential superiority of second-generation
(atypical) antipsychotics over first-generation antipsychotics. Tandon et al. (2008) examined the
effectiveness of 62 antipsychotic (51 first-generation and 11 second-generation) medications
using data from about 1,600 clinical trials and concluded that second-generation antipsychotics
were as effective as first-generation antipsychotics with regard to treating positive symptoms
(Tandon et al., 2008). However, the superior benefits of second-generation medications for
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negative symptoms, cognition, and depression were not consistently demonstrated (Tandon et al.,
2008). The atypical antipsychotic clozapine was superior to the first-generation antipsychotics
and the other second-generation antipsychotics, and also had the most benefit for treatmentresistant psychosis (Tandon et al., 2008). Nevertheless, due to the risk of neutropenia (i.e.,
excessively low numbers of white blood cells) clozapine is reserved for people who have failed
two or more trials of antipsychotic medications (Tandon et al., 2008).
Keating et al. (2017) concluded that consideration of medication side effects is the most
important factor in selecting an antipsychotic medication. Atypical agents, compared to
neuroleptic medications, have a lower risk of extrapyramidal side effects (i.e., muscle tightening
or movement problems) and tardive dyskinesia (Tandon et al., 2008). However, secondgeneration medications generally pose greater risks for the metabolic effects of weight gain,
diabetes, and dyslipidemia, all of which are risk factors for heart disease and increased mortality
(Tandon et al., 2008). Metabolic side effects vary by agent among the atypical antipsychotics,
with clozapine and olanzapine resulting in the greatest degree and ziprasidone causing the least
(Tandon et al., 2008). The balanced risk of adverse side effects should be considered when
selecting the best psychotropic medication for a particular individual.
The Schizophrenia PORT also generated several treatment recommendations based on
systematic reviews of existing literature (Kreyenbuhl, Buchanan, Dickerson, & Dixon, 2010).
Pharmacological treatment recommendations paralleled those suggested by Tandon et al. (2008),
but Kreyenbuhl et al. (2010) extended their systematic analysis further by investigating existing
psychosocial treatment recommendations. Medications fail to adequately treat negative
symptoms; thus, psychosocial treatments are critical for enhancing quality of life and medication
adherence (Elis, Caponigro, & Kring, 2013). For example, cognitive behavioral therapy was
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effective in reducing symptom severity, and family-based services of at least 6 to 9 months in
duration helped to significantly decrease rates of relapse (Kreyenbuhl et al., 2010). A key factor
in family therapy is addressing the issue of expressed emotion, “an empirically derived index of
criticism, overinvolvement, and hostility” (p. 164), by family members of individuals with
schizophrenia (Bustillo, Laurielle, Horan, & Keith, 2001). Research has shown that changes in
expressed emotion (from higher to lower levels) are associated with decreased rates of relapse
(Bustillo et al., 2001).
Risk Factors for Deterioration/Hospitalizations. According to Keating et al. (2017),
relapse (i.e., a worsening of symptoms after a period of improvement or return of symptoms
following remission) occurs in about 3 out of 4 people with schizophrenia. Weiden, Kozma,
Grogg, and Locklear (2004) examined 4,325 Medicaid pharmacy refill and claims forms of
individuals with schizophrenia to determine the relationship between adherence to antipsychotics
and hospitalization. Results indicated that even small gaps in medication adherence (i.e., 1 to 10
days) significantly increased the likelihood of hospitalization (Weiden et al., 2004). Results also
showed that hospitalization occurred more frequently among Black individuals and among
Medicare-eligible individuals (Weiden et al., 2004). Other studies suggest that relapse is strongly
associated with lower premorbid functioning (Üçok, Polat, Çakır, & Genç, 2006), co-occurring
substance use disorders (SUD; Malla et al., 2008), and lack of insight (Drake et al., 2007).
Further, as previously noted, higher levels of expressed emotion within families are associated
with increased rates of relapse (Bustillo et al., 2001).
Approximately 11% of the homeless population has schizophrenia, and this type of living
arrangement is associated with worse outcomes (Foster, Gable, & Buckley, 2012). Many
individuals with schizophrenia who are homeless receive subpar service planning, as well as
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discontinue using available treatment (Foster et al., 2012). Individuals with SMI who are
homeless may discontinue their medication regimens because they are not closely monitored in
the community; as a result, many deteriorate quickly and are hospitalized (Lamb & Bachrach,
2001).
Schizoaffective Disorder
Prevalence and Incidence. According to the APA (2013), schizoaffective disorder is not
as common as schizophrenia and has a lifetime prevalence rate of 0.3%. Incidence rates are
unclear due to recent changes in diagnostic criteria (Brannon, 2012). Prior to the DSM-5, the
diagnosis was used more frequently than intended. Current criteria emphasize the lifetime course
of the illness, as opposed to consideration of potentially isolated episodes described in previous
manuals (Malaspina et al., 2013). The change is intended to ensure that criteria are consistently
applied, which ultimately will lead to reduced rates of schizoaffective diagnoses (Malaspina et
al., 2013).
Symptoms and Primary Diagnostic Criteria. In order to establish a diagnosis of
schizoaffective disorder, an episode of a mood disorder must occur along with an active phase of
schizophrenia (APA, 2013). In addition, there must also be a period of at least 2 weeks of
hallucinations or delusions without a mood episode (in order to rule out a psychotic mood
disorder), mood episodes must occur over most of the active and residual phases of the disorder,
and symptoms cannot be the result of a substance or some other health condition (APA, 2013).
Gender and Race Considerations. Women are more likely than men to receive a
diagnosis of schizoaffective disorder (APA, 2013), and a study by Robinson et al. (1999) found
that female participants with first-episode schizoaffective disorder responded better to
antipsychotics than did male participants. Although Black individuals are more likely to receive
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a diagnosis of schizophrenia than White individuals, racial differences are not apparent among
individuals diagnosed with schizoaffective disorder (Neighbors, Trierweiler, Ford, & Muroff,
2003).
Best Practices and Treatment Characteristics. According to Levinson, Umapathy, and
Musthaq (1999), the majority of individuals diagnosed with schizoaffective disorder are treated
with antipsychotics, thymoleptics (i.e., drugs that modify mood), antidepressants, or a
combination of medications. Levinson et al. (1999) examined 18 treatment studies of
schizoaffective disorder and found that antipsychotics alone were just as effective as
combinations when treating acute symptoms; however, once psychotic symptoms were in
remission, a combination of both antidepressants and antipsychotics helped alleviate symptoms
of major depression (Levinson et al., 1999). On the other hand, lithium (a thymoleptic) was not
effective in treating depressive symptoms or mania (Levinson et al., 1999).
Risk Factors for Deterioration/Hospitalizations. As with schizophrenia, the risk of
relapse is common among individuals with schizoaffective disorder (Gaebel et al., 2010).
Robinson et al. (1999) sought to determine the characteristics associated with relapse among
individuals with first-episode schizophrenia (N=71) and schizoaffective disorder (N=33) who
had achieved remission following initial episodes and found that nonadherence to antipsychotic
medication made relapse 5 times more likely. In addition, Robinson et al. (1999) demonstrated
that poor premorbid functioning and social withdrawal correlated with earlier relapse and that
despite careful monitoring, second and third relapses were common among individuals who had
recovered from first relapses. Murru et al. (2012) completed a longitudinal study with 76
individuals diagnosed with schizoaffective disorder and found that individuals who did not
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adhere to treatment recommendations (N=32) primarily experienced psychotic (non-affective)
symptom episodes.
Brief Psychotic Disorder
Prevalence and Incidence. According to the APA (2013), approximately 9% of all firstonset psychotic disturbances in the United States meet criteria for brief psychotic disorder.
Castagnini, Bertelsen, and Berrios (2008) found that the median incidence of brief psychotic
disorder is roughly 9.6 per 100,000 persons annually. Women are twice as likely as men to
receive a diagnosis of brief psychotic disorder, and the condition occurs more frequently in
developing countries (APA, 2013).
Symptoms and Primary Diagnostic Criteria. In order to establish a diagnosis of brief
psychotic disorder, delusions, hallucinations, or disorganized speech must occur for at least 1
day, but for no more than 1 month (APA, 2013). The episode may also include disorganized
behavior or catatonia. The psychosis may occur with or without a stressor, and it may appear in a
peripartum period (APA, 2013). In addition, any psychosis associated with a mood episode, the
influence of a substance, and the effect of a medical condition must be ruled out (APA, 2013).
Best Practices and Treatment Considerations. With brief psychotic disorder, the goal
of treatment is to help individuals return to their previous level of functioning (APA, 2013).
According to Memon (2015a), symptoms of brief psychotic disorder should be treated with
antipsychotic medications, and because psychotic episodes are time limited, medication regimens
should not extend beyond 1 month. Currently, there is no evidence supporting the superiority of
atypical agents over neuroletpics in treating the disorder (Memon, 2015a). Intramuscular
ziprasidone (Brook, Lucey, & Gunn, 2000) and rapid tranquilization with olanzapine (Karagianis
et al., 2001) have been demonstrated to be effective in treating acute psychotic aggression.
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Individuals with brief psychotic disorder are at greater risk of harming themselves and others
during acute episodes (Jorgensen & Mortensen, 1990). Thus, Memon (2015a) recommends
hospitalization if safety is a concern.
Risk Factors for Deterioration/Hospitalizations. Typically, brief psychotic disorder
has a good prognosis, and 50-80% of those diagnosed experience no major subsequent
psychiatric issues (Memon, 2015b). Correll et al. (2008) observed that individuals with brief
psychotic disorder who also demonstrate executive functional deficits may go on to develop
schizophrenia; whereas those with co-occurring brief psychotic disorder and anxiety symptoms
may eventually develop bipolar disorder (Correll et al., 2008).
Stigma and Its Consequences
According to Stuart and Arboleda-Flórez (2012), “Mental illness stigma occurs when
individuals are devalued or treated unfairly by others because of their mental health condition”
(p. 1). Despite increased public awareness of mental illnesses, people with mental disorders are
still among the most stigmatized groups in society (Stuart & Arboleda-Flórez, 2012), and this
burden extends to family members, as well as to mental health providers, whose careers are not
acknowledged and valued as much as those of professionals in other health disciplines (Sartorius,
2002).
Data collected from the general public and from those with mental disorders indicate
widespread prevalence of mental illness stigma. For example, Angermeyer and Deitrich (2006)
reviewed national (N=33) and local (N=29) surveys of public attitudes to determine the
magnitude of mental health stigma and found that individuals with schizophrenia or SUD
received less sympathy and more social rejection than individuals with depression. Pescosolido,
Monahan, Link, Stueve, and Kikuzawa (1999) extracted a random sample of interviews
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(N=1,444) from the 1996 General Social Survey, which prompted respondents to evaluate the
competence of individuals in a variety of case vignettes. The majority of respondents believed
that individuals with schizophrenia were incapable of making treatment decisions (75.3%),
unable to manage money (70.2%), and likely to commit violent acts against others (60.9%). The
belief that persons with mental illness are violent is one of many prejudices held by the public at
large, and these attitudes engender discriminatory actions against individuals with mental
disorders (Arboleda-Flórez & Sartorius, 2008).
Wahl (1999) conducted a large-scale survey of people with mental illness in order to
examine the impact of stigma on their lives. Of the 1,388 individuals who completed the survey,
74% indicated that they avoided disclosing their mental health diagnoses to non-family
members, 71% denied having a mental illness on applications to evade discrimination, 31%
reported having been turned down for a job due to their mental illness, and 10% reported
hesitancy to seek treatment due to fear of judgment (Wahl, 1999). Thornicroft et al. (2009)
surveyed 732 individuals with schizophrenia across 27 countries and found that almost half
(47%) of the respondents reported experiencing some type of discrimination (e.g., inability to
make or keep friends, judgment by family members, trouble finding and keeping work, difficulty
finding a romantic partner). Most notably, almost three fourths (72%) of respondents reported
concealing their diagnoses to avoid anticipated discrimination (Thornicroft et al., 2009). A study
by Brohan, Elgie, Sartorius, Thornicroft, and GAMIAN-Europe Study Group (2010) analyzed
1,229 surveys from individuals diagnosed with schizophrenia or other psychotic disorders and
found that 69% believed that the general population thought negatively about them, 48%
experienced discrimination, 47% suffered alienation, and 45% resorted to social withdrawal.
Stuart and Arboleda-Flórez (2012) underscored the negative impact of stigma on recovery and
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recommended that mental health professionals promote client empowerment, identify prevention
strategies, and educate the public about common misconceptions.
A substantial portion of the general public erroneously believes that individuals with
schizophrenia and other thought disorders are inherently violent, and Lamb and Bachrach (2001)
suggest that some of these misconceptions might stem from the collateral effects of
deinstitutionalization. In 1955, approximately 559,000 individuals with SMI occupied state
mental hospital beds, a number that drastically decreased to only 57,151 in 1998 (Lamb &
Bachrach, 2001). During this period, proponents of deinstitutionalization believed that
community-based care would be more humane, beneficial, and cost-effective than state hospital
care (see, e.g., Bachrach, 1976; Bachrach, 1978; Thornicroft & Bebbington, 1989). However,
many deinstitutionalized individuals with SMI received fragmented services and were not
provided affordable housing options (Carling, 1993; Räsänen et al., 2000), and large numbers
became homeless (Lamb & Bachrach, 2001). Baum and Burnes (1993) estimated that as much as
one half of all individuals who are homeless have some type of SMI, a vulnerable group at risk
of deteriorating quickly from improper treatment and the effects of substance use (Lamb &
Bachrach, 2001). Alcohol and illicit drug use contribute to medication nonadherence and can
exacerbate symptoms, which may result in bizarre behavior; and individuals with SMI who
exhibit odd behavior in public are often inappropriately arrested and incarcerated (Lamb &
Bachrach, 2001).
In the 1970s and 1980s, due to major policy changes and inadequate community-based
treatment, the criminal justice system increasingly assumed the role of state hospitals (Borzecki
& Wormith, 1985). In fact, Foderaro (1994) reported that by the 1990s, there were more
individuals with SMI in jails and prisons than in psychiatric hospitals. The criminalization of
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mental illness is a complex and multifaceted contemporary public health issue, and changes on
multiple levels must be implemented to ensure that those with SMI are provided with appropriate
community-based treatment and support (Lamb & Bachrach, 2001). In addition, Stuart and
Arboleda-Flórez (2012) assert that challenging mental health stigma is a public health priority
and that initiatives to redress discrimination are needed to ameliorate existing social disparities.
In sum, thought disorders can be debilitating for affected individuals, so practitioners
must be knowledgeable about the prevalence, diagnostic criteria, effective pharmacological and
psychosocial interventions, and relevant risk factors. Treatment of individuals with schizophrenia
and other thought disorders typically involves antipsychotic medications (Chien & Yip, 2013);
however, second-generation antipsychotics cause a variety of metabolic side effects (e.g., weight
gain, dyslipidemia), which may lead to the development of chronic health diseases (Tandon et
al., 2008). These side effects, in addition to other factors affecting health status, result in
individuals with thought disorders being disproportionately affected by comorbid physical health
conditions.
Comorbidity, Risk Factors, and the Importance of Screening
It is well established that individuals with SMI live, on average, 25 years less than
individuals without SMI (Parks, Svendsen, Singer, & Foti, 2006). According to Parks et al.
(2006), preventable physical health conditions (e.g., cardiovascular disease, pulmonary disease,
infectious disease) account for 60% of early deaths in individuals diagnosed with schizophrenia,
and several of the risk factors (e.g., smoking, alcohol consumption, drug use, poor nutrition,
sedentary lifestyle) that contribute to these physical health conditions are modifiable (Parks et
al., 2006). Efforts have been made to address this public health crisis through federally-supported
grants (Scharf et al., 2013), discussed below.
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Comorbidity Among Individuals With Thought Disorders
Extant research shows that certain cardiometabolic conditions (e.g., obesity,
hypertension, high blood sugar, elevated triglyceride [TRI] levels, reduced high-density
lipoprotein [HDL] levels) increase an individual’s chances of developing diabetes, heart disease,
or stroke (De Hert et al., 2011). This section reviews statistics drawn from a variety of sources
that describe the co-occurrence of physical health conditions and diseases among individuals
with SMI, with a special focus on individuals with schizophrenia and other thought disorders.
The prevalence rates of comorbid health conditions and largely preventable diseases are
higher among individuals with schizophrenia and schizoaffective disorder. Correll et al. (2010)
conducted a large-scale study of 10,084 individuals with mental illness and found that among
individuals with schizophrenia, 79% were overweight or obese, 52% had metabolic syndrome,
51% had hypertension, 40% had hypertriglyceridemia, 37% had hyperglycemia, and 30% had
dyslipidemia. The National Comorbidity Survey Replication (N=9,282) determined that
approximately 68% of adults with mental disorders, including those with diagnoses on the
schizophrenia spectrum, had at least one co-occurring physical health condition (Alegria,
Jackson, Kessler, & Takeuchi, 2003). In a large-scale, population-based study, Carney, Jones,
and Woolson (2006) found that individuals with schizophrenia and schizoaffective disorder were
significantly more likely than control group participants (with no mental disorders) to have one
or more chronic health conditions, and of the 1,074 participants with thought disorders, 33% had
three or more chronic health conditions. Carney et al. (2006) further reported that individuals
with thought disorders were more likely than controls to experience health conditions across
multiple organ systems, as well as experience co-occurring substance abuse and dependence (i.e.,
alcohol, illicit drugs, nicotine).

19

Smaller-scale studies have demonstrated similar results. For example, Baughman et al.
(2016) compared health information from 203 adults with SMI to similar data collected from a
matched sample of adults without SMI and found that individuals with SMI had higher
prevalence rates of 7 out of 9 chronic diseases (i.e., chronic pain, respiratory problems, arthritis,
cardiovascular disease, headaches, diabetes, ulcers in the stomach/intestine; Baughman et al.,
2016). Jones et al. (2004) examined a subsample of Medicaid claims of adults diagnosed with
SMI (e.g., schizophrenia, schizoaffective disorder) to determine the prevalence of comorbid
physical conditions. Of the 147 cases reviewed, 75% of participants had at least one chronic
health condition, and 50% had two or more chronic health conditions (Jones et al., 2004). The
most common chronic health problem was pulmonary illness, at 31% (Jones et al., 2004).
Diabetes is a notable problem among persons with schizophrenia due to obesity. These
individuals are 2 times more likely than the general population to develop diabetes, and they are
more likely to develop the condition at a younger age (De Hert et al., 2010). Additionally,
individuals with schizophrenia (and other thought disorders) and comorbid diabetes experience a
more complicated course of the disease than is experienced by the general population (Carney et
al., 2006). This disproportionate rate of diabetes likely can be explained by obesity, which often
predicts the development of the disease (Gough, 2005). For example, Coodin (2001) showed
that persons with schizophrenia are 2.8 to 3.5 times more likely than the general population to be
obese. In addition, a study of 262 adults with SMI (i.e., schizophrenia, schizoaffective disorder,
bipolar disorder) found that individuals with schizoaffective disorder had the highest rates of
obesity, after controlling for relevant demographic characteristics (Chouinard et al., 2016).
Descriptive studies of individuals with comorbid mental disorders and physical health
conditions have examined differences across gender and race. Lemieux, Richards, Hunter, and
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Kasofsky (2015), for example, examined individuals (N=125) receiving integrated health
services at 3 different CMH centers and determined that female participants had significantly
more comorbid physical health conditions (0.86) than male participants (0.53). In addition,
women reported comorbid cardiac disease at a rate 4 times that of men (at 22.1% and 5%,
respectively; Lemieux et al., 2015). Gleason et al. (2014) also examined gender differences
between men (N=167) and women (N=144) receiving integrated services in a CMH setting.
Analyses showed that female participants had significantly higher waist circumference and body
mass index (BMI) scores, as compared to men (Gleason et al., 2014). Although more men than
women had hypertension, men and women were equally at risk for developing diabetes and
metabolic syndrome (Gleason et al., 2014).
Racial differences also emerged in the study by Lemieux et al. (2015). Blacks were more
likely than Whites to have more comorbid conditions, as well as show higher BMI and blood
pressure (BP) scores (Lemieux et al., 2015). Conversely, Whites had higher low-density
lipoprotein (LDL) and TRI scores than Blacks (Lemieux et al., 2015).
Risk Factors for Developing Comorbid Health Conditions
This section provides an overview of identified factors that place individuals with SMI at risk for
developing physical health conditions, namely smoking, substance use, poor nutrition, sedentary
lifestyle, and medication side effects. Research shows that the majority of these risk factors are
modifiable (Parks et al., 2006).
Smoking. According to the Centers for Diseases Control and Prevention (CDC, 2013),
smoking is the primary cause of preventable diseases and deaths in the United States. Results
from the 2009-2011 National Survey on Drug Use and Health revealed that 36% of adults with
mental illness smoke as compared to 21% of adults without mental illness (SAMHSA, 2011).
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Results also showed that smokers with mental illness were less likely to quit than smokers
without mental illness, despite the fact that many indicated a desire to do so (SAMHSA, 2011).
Hartz et al. (2014) conducted a large-scale study of smoking and compared individuals
with severe psychotic disorders (i.e., bipolar disorder with psychosis [N=1,507], schizoaffective
disorder [N=2,037], schizophrenia [N=5,586]) to individuals without the conditions (N=10,311).
Results showed that individuals with psychotic disorders were far more likely than control
participants to have smoked at least 100 cigarettes in a lifetime (bipolar disorder with psychosis
[74%], schizoaffective disorder [79%], schizophrenia [74%], control participants [33%]) and to
be daily smokers (bipolar disorder with psychosis [71%], schizoaffective disorder [77%],
schizophrenia [72%], control participants [29%]; Hartz et al., 2014). Dickerson et al. (2013)
examined 991 individuals with schizophrenia (N=421), bipolar disorder (N=126), and no
psychiatric illnesses (N=444) and found that 64% of if the individuals with schizophrenia, 44%
of the individuals with bipolar disorder, and 19% of the individuals without psychiatric illnesses
smoked. Subsequent analyses determined that the following characteristics were strongly
associated with higher rates of cigarette consumption among those with SMI: male gender, cooccurring substance use, White race, and lower education level (Dickerson et al., 2013).
Studies have attempted to determine the cause of increased rates of smoking among
individuals with schizophrenia and other thought disorders. Miller (1977) hypothesized that
individuals who take first-generation antipsychotics smoke to reduce extrapyramidal side effects
associated with the medications. Higher rates of smoking might also be explained by central
nervous system tolerance, associated with long-term use of nicotine (Adler et al., 1998).
Additionally, some individuals might be seeking the reduction of anxiety or elevation of mood
that can result from nicotine usage (Kirch, Gerhardt, Shelton, Freedman, & Wyatt, 1987).
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Finally, because persons with schizophrenia have problematic function of nicotinic acetylcholine
receptors, these individuals might smoke to generate a pharmacodynamics effect (i.e., activation
of neuronal receptors by the substance; Adler et al., 1998).
Alcohol and Other Substance Use. According to SAMHSA (2016), approximately 1%
of adults in the United States (an estimated 2.3 million) have co-occurring SMI and SUD.
Although the use of certain substances is known to ameliorate negative symptoms of psychotic
disorders (e.g., anhedonia, boredom; Batel, 2000), individuals with co-occurring SUD are more
prone to adverse events, such as exacerbated psychotic symptoms, poorer medication
compliance, homelessness, and a variety of preventable physical health problems (Dixon, 1999).
Dixon (1999) suggested that roughly 50% of all individuals with schizophrenia struggle
with co-occurring SUD, and most frequently misuse alcohol and marijuana. Hartz et al. (2014)
examined 5,586 individuals with schizophrenia and found that 28% consumed more than 4
drinks a day, 43% smoked marijuana more than 21 times a year, and 35% had used other
recreational drugs more than 10 times during their lifetime. However, rates were slightly higher
for participants diagnosed with schizoaffective disorder (N=2,037): 29% consumed more than 4
drinks a day, 53% smoked marijuana more than 21 times a year, and 52% had used other
recreational drugs more than 10 times during their lifetime (Hartz et al., 2014).
According to Hartz et al. (2014), rates of substance use vary markedly across race and
gender in the general population. For example, among participants in the control group
(N=10,311), Whites had higher rates of substance use than Hispanics and Asians, and men had
higher rates than women. However, these demographic differences were not evident among
individuals with severe psychotic disorders, whose rates of use were relatively consistent across
race and gender (Hartz et al., 2014).
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Poor Nutrition. According to Peet (2003), numerous studies have linked poor nutrition
to the development of heart disease, diabetes, and several cancers, and it is well known that
many persons with schizophrenia have substandard diets. Dipasquale et al. (2013) reviewed 31
studies of nutrition among individuals with schizophrenia and found that the majority of
participants consumed large amounts of saturated fats and small amounts of fiber and fruit.
Strassnig, Brar, and Ganguli (2003) administered a nutrition assessment to 146 psychiatric
patients with schizophrenia, schizoaffective disorder, and other psychotic disorders and
compared their responses to an age-adjusted group from the general population. Results revealed
that percentages of intake for protein, carbohydrates, and fat were not different between the two
groups; however, individuals with schizophrenia ate higher quantities of food (Strassnig et al.,
2003).
Studies have attempted to determine the reasons for dietary differences between
individuals with schizophrenia and the general population. Suvisaari, Keinänen, Eskelinen, and
Mantere (2016) suggested that poverty could be a major barrier to obtaining higher-quality
foods. Further, atypical antipsychotics might increase hunger sensations, which ultimately results
in overeating (Blouin et al., 2008).
Sedentary Lifestyle. According to Mokdad, Marks, Stroup, and Gerberding (2004), low
levels of physical activity and poor diet are the second leading causes of death in the United
States and may become the leading causes of death in the country. Rates of chronic diseases are
prevalent among individuals with SMI; thus, this population could experience substantial
benefits from increased levels of physical activity (Daumit et al., 2005). Blair et al. (1995) found
that even after years of inactivity, people can significantly improve their health by increasing
their levels of exercise.
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Galletly et al. (2012) collected data from 1,825 outpatients, including individuals with
schizophrenia (N=857) and schizoaffective disorder (N=293), and found that almost all (96.7%)
participants engaged in low (63.1%) or very low (33.6%) levels of physical activity. Gender
differences in level of physical activity were not evident; however, younger individuals were
more likely to report low levels of physical activity, and older adults were more likely to report
very low levels of physical activity (Galletly et al., 2012). Daumit et al. (2005) conducted a
smaller-scale study comparing 185 individuals with SMI (including individuals with
schizophrenia and schizoaffective disorder) to a subset of individuals from the National Health
and Nutrition Examination Survey (N=2,705). Results showed that over one fourth of individuals
with SMI (25.7%) engaged in no physical activity during the previous month, as compared to
controls, at 17.5% (Daumit et al., 2005).
Researchers have attempted to determine the reason for low levels of physical activity
among individuals with thought disorders. Negative symptoms might inhibit the desire to
maintain adequate levels of physical activity (Lambert, Velakoulis, & Pantelis, 2003). Suvisaari
et al. (2016) suggested that individuals with schizophrenia might be less able to afford gym
memberships (due to low socioeconomic status) and that this obstacle might also contribute to
subpar levels of physical activity levels.
Medications. Second-generation antipsychotics significantly increase the likelihood of
gaining weight and developing diabetes and dyslipidemia, and specific agents (e.g., clozapine
and olanzapine) are associated with even higher rates of these metabolic conditions (Tandon et
al., 2008). Allison et al. (1999) conducted a meta-analysis of 81 studies to determine the impact
of various antipsychotic medications on weight after 10 weeks of standard dosages of included
agents. Results revealed that the first-generation drug molindone was associated with a mean
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weight reduction of 0.39 kg; however, the other analyzed conventional antipsychotic,
thioridazine, was associated with a mean weight gain of 3.19 kg (Allison et al., 1999). All
atypical antipsychotics included in the research synthesis were associated with weight increases:
clozapine (4.45 kg), olanzapine (4.15 kg), sertindole (2.92 kg), risperidone (2.10 kg), and
ziprasidone (0.04 kg).
Although first-generation medications are less likely to cause these adverse metabolic
effects (Smith et al., 2008), physicians might be hesitant to prescribe them because of
extrapyramidal side effects and risk of developing tardive dyskinesia (Tandon et al., 2008).
According to Keating et al. (2017), consideration of all medication side effects is the most
important factor in selecting an antipsychotic medication.
The Importance of Screening
According to Parks et al. (2006), early detection is key to reducing rates of
cardiometabolic conditions among individuals with SMI. Providers should systematically track
mechanical (i.e., BMI, systolic BP, diastolic BP) and laboratory (i.e., blood glucose, HDL, LDL,
TRI) health indicators in order to effectively monitor the physical health of individuals with SMI
(Parks, Radke, Mazade, & Mauer, 2008). BMI is used to detect obesity, a condition that leads to
increased risk of diabetes, heart disease, and hypertension (Parks et al., 2008). Monitoring BP is
important, as higher BP predisposes individuals to developing heart disease, hypertension, and
stroke (Parks et al., 2008). Increased HDL is associated with lower risk of heart disease and
serves as a protective factor; conversely, higher LDL and TRI are associated with diabetes, heart
disease, and obesity (Parks et al., 2008). In addition to routine monitoring, Parks et al. (2008)
also noted the importance of gathering family and personal history of cardiometabolic
conditions, along with personal history of alcohol, drug, and tobacco use.
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Screening is important for primary, secondary, and tertiary health interventions (Parks et
al., 2008). Individuals without cardiometabolc conditions should be screened regularly and
encouraged to participate in activities that prevent the development of these conditions (Parks et
al., 2008). When cardiometabolic conditions are present, individuals with SMI should be linked
to specific wellness interventions to improve their prognosis and to prevent the development of
chronic diseases (e.g., diabetes, hearth disease, or stroke; Parks et al., 2008). Finally, individuals
diagnosed with comorbid diseases should be frequently monitored in order to restore functioning
and to prevent the development of disease-related complications (Parks et al., 2008).
Treatment Utilization and Barriers Among Individuals with Thought Disorders
Despite the high prevalence rates of physical health conditions among individuals with
SMI, they are less likely to visit physicians for routine medical care than the general population
(Druss & Walker, 2011; Lu et al., 2008; Roesenberg et al., 2007). Cradock-O’Leary, Young,
Yano, Wang, and Lee (2002) reviewed 175,653 patient records from the Department of Veterans
Affairs (VA) databases to analyze medical care usage and found that individuals with SMI had
far fewer medical visits than those without any type of mental illness. Young male adults with
schizophrenia, in particular, had an elevated risk for not receiving medical care (CradockO’Leary et al., 2002). Correll et al. (2010) offered free metabolic screenings to 10,084 patients
with mental illness, including schizophrenia, in order to determine rates of undertreatment of
medical conditions. Of the adult participants with schizophrenia, 57% of those with
dyslipidemia, 56% of those with metabolic syndrome, 49% of those with hypertension, and 41%
of those with diabetes reported having received no treatment for the conditions (Correll et al.,
2010).
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Extant research indicates that individuals with SMI tend to overuse emergency services
for medical care (Hackman et al., 2006; Salsberry, Chipps, & Kennedy, 2005) because of
inadequate access and numerous barriers to routine and preventative care (Parks et al., 2006).
Miller et al. (2003), for example, surveyed 59 CMH clients about access to primary care and the
quality of that care and found that almost two thirds (63%) could not identify the names of their
primary care providers offhand. Of the individuals who did have a consistent source of primary
care (14%), many reported relying on emergency services for their physical health issues (Miller
et al., 2003). Finally, for those who reported receiving some type of primary care, scores on the
Primary Care Assessment Tool showed that participants were receiving less than ideal care, in
that mental health providers often failed to ask about physical conditions, and, conversely,
medical providers failed to ask about mental health issues (Miller et al., 2003).
Individual factors also contribute to disparities in health care utilization (Druss & Walker,
2011). Paranoia and negative symptoms (e.g., amotivation) may prevent individuals with thought
disorders from obtaining needed medical treatment (Parks et al., 2006). Others are hesitant to
seek treatment out of fear of judgment (Wahl, 1999). Socioeconomic circumstances may also
play a role. Studies by Gleason, Truong, Biebel, Hobart, and Kolodziej (2017) and Thomas
(2017) showed that access to transportation was associated with treatment engagement.
Providers also create barriers to adequate primary care in both physical and behavioral
health settings. Druss and Walker (2011) suggested that stigma surrounding mental illness might
discourage primary health providers from treating persons with SMI. Conversely, psychiatrists
might feel ill prepared to treat the various medical needs of people with SMI (Druss & Walker,
2011). Gleason et al. (2017) further found that inconvenient appointment times were also barriers
to treatment engagement. However, Parks et al. (2006) maintained that the principal barrier to
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satisfactory primary care is the poor coordination between multiple providers that operate in
separate systems of health care.
The Importance of an Integrated Health Approach
An integrated health approach directly addresses fragmentation between separate systems
of care. Integrated care, broadly speaking, refers to health care arrangements that combine
primary and mental health services in the same setting (Scharf et al., 2013). According to
Gerrity, Zoller, Pinson, Pettinari, and King (2014), integrated PBHC programs use different
strategies to coordinate physical and mental health care services for persons with multiple
chronic conditions, including SMI. There are several models of integrated care: coordinated, colocated, and fully integrated (Heath, Wise, Romero, & Reynolds, 2013). Coordinated care
involves communication between providers of separate facilities (Heath et al., 2013). This
particular model of integration typically utilizes care managers who can provide outside referrals
to clients, assist clients in connecting with external resources, and follow up with clients’ various
providers (Druss & Walker, 2011). Co-located care involves the provision of physical health
services in CMH centers or, conversely, mental health treatment in primary care clinics (Heath et
al., 2013). This particular integrated PBHC model is a feasible alternative when full integration
is not possible (Druss & Walker, 2011). Finally, fully integrated PBHC organizations, such as
the VA (Druss & Walker, 2011), have the capacity to provide all necessary physical and mental
health services to individuals with comorbid conditions (Heath et al., 2013).
Little research has evaluated interventions to improve the physical health of persons with
SMI (Druss, Rohrbaugh, Levinson, & Rosenheck, 2001; Kilbourne et al., 2008), and most of the
existing research on integrated treatment approaches has been conducted within fully integrated
organizations, such as the VA (Druss & Walker, 2011). In 2015, approximately two thirds of
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adults with SMI reported receiving behavioral health services during the previous year (65.3%;
SAMHSA, 2016). Individuals with SMI are more likely to seek health care services through
CMH centers, thus, these agencies are the ideal locations to provide coordinated care (Druss et
al., 2010).
Druss et al. (2008) surveyed CMH centers across the country to assess their capacity to
provide primary care services to clients. Of the 181 CMH centers that responded, the majority
routinely screened for hypertension (80%) and for obesity (72%), but less than half screened for
diabetes (47%) and dyslipidemia (44%). Other sites referred clients out for medical screenings
(Druss et al., 2008). Although well over two thirds (71%) of the CMH centers reported an ability
to provide on- or off-site medical screenings, only about half (51%) reported having the capacity
to provide treatment for identified medical problems (Druss et al., 2008). Respondents reported
several barriers to provision of medical services, including issues around reimbursement (72%),
limited staff (69%), physical space limitations (61%), and a lack of community referral options
(56%; Druss et al., 2008).
SAMHSA funded the Primary and Behavioral Health Care Integration (PBHCI) grants
program to improve the overall health of individuals with SMI via co-location of various primary
care services in CMH settings (Scharf et al., 2013). CMH centers that received grant funding
were required to provide physical health screenings and referrals, develop a health needs and
outcomes tracking system, offer care management services, and implement wellness programs
(Scharf et al., 2013). In an uncontrolled evaluation, the RAND Corporation assessed the success
of the PBHCI grants program and reported many accomplishments, including the establishment
of multidisciplinary teams that offered a variety of wellness programs (Scharf et al., 2013).
However, grantees also experienced several unforeseen challenges (e.g., low consumer
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enrollment, issues with financial sustainability, communication problems between team
members; Scharf et al., 2013). Nevertheless, Scharf et al. (2013) concluded that the PBHCI
program, overall, was successful in creating necessary services for underserved and vulnerable
community-based populations, and they suggested that efforts should be made to increase
consumer access to integrated PBHC services and that strategies should be developed to improve
sustainability.
Although efforts have been made to implement integrated services in CMH settings, few
studies have evaluated the impact of these programs on health outcomes (Gerrity et al., 2014).
The Primary Care Access and Referral (PCARE) study by Druss et al. (2010) randomly assigned
CMH clients to either care management services (N=205) or to usual care (N=202). Nurse care
managers educated treatment group participants about their medical conditions, provided them
with specialty referrals, and created action plans with them mapping out medical care and
lifestyle change goals. At 12 months out, well over half of the participants in the care
management intervention group received primary services (58.7%), a rate almost twice that of
participants in the control group (21.8%; Druss et al., 2010). Lab work indicated that the risk of
developing cardiovascular disease decreased by 11.8% in the treatment group, but increased by
19.5% in the control group. Additionally, a greater number of previously undiagnosed physical
health conditions were discovered in the care management group (Druss et al., 2010). These
latter results are promising in terms of the potential effectiveness of co-located care, given that
most CMH centers do not have the resources to provide fully integrated services.
In an uncontrolled evaluation study, Putz et al. (2015) collected longitudinal data from a
sample of 169 adults with SMI receiving a collaborative care intervention at a CMH center.
Participants received comprehensive health assessments upon program entry, were assigned a

31

case manager, and were offered a variety of wellness programs. At 6 months out, significant
improvements in health outcomes were observed, including weight loss, decreases in smoking
and LDL, and increases in HDL (Putz et al., 2015). Results demonstrated by Druss et al. (2010)
and Putz et al. (2015) suggest that co-located integrated health approaches resulted in improved
outcomes for CMH clients with SMI.
SMI, Treatment Disengagement, and Treatment Retention
Treatment engagement is critical for individuals with SMI, as those who drop out are at
greater risk of experiencing increased morbidity (Davis et al., 2012), intensified psychiatric
symptoms, frequent hospitalizations, homelessness, legal problems, and suicidal ideation (Dixon
et al., 2009; Fischer et al., 2008). According to Druss and Walker (2011), ongoing contact with
providers helps individuals with SMI to manage symptoms and medications. Adair et al. (2005)
conducted a longitudinal study of 486 adults with SMI to examine the relationship between
continued care and health outcomes and found that treatment continuity was associated with
better quality of life, improved functioning, reduced symptom severity, and increased service
satisfaction. Adair et al. (2005) suggested that efforts should be made in health settings to
improve continuity of care, which was defined by Bachrach (1981) as “a process involving the
orderly, uninterrupted movement of patients among the diverse elements of the service delivery
system” (p. 1449).
The majority of individuals with SMI often do not complete the recommended course of
treatment (Wang, 2007; Wang et al., 2000). Olfson et al. (2009) examined a subsample of
individuals (N=1,664) with various psychiatric diagnoses from the National Comorbidity Survey
Replication in order to determine patterns and predictors of primary care and mental health
treatment dropout. Results indicated that over one fifth of participants (22.4%) dropped out of
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treatment prematurely and that individuals were more likely to discontinue primary care services
(31.6%) than mental health services (15.1%; Olfson et al., 2009). Analyses revealed that Blacks
were more likely than Whites to discontinue treatment and that younger individuals were more
likely than older individuals to withdraw from care (Olfson et al., 2009). Education level and
employment status, however, were negatively associated with treatment disengagement (Olfson
et al., 2009).
Kreyenbuhl, Nossel, and Dixon (2009) also sought to determine patterns and predictors
of treatment dropout. However, unlike Oflson et al. (2009), Kreyenbuhl et al. (2009) exclusively
focused on mental health treatment disengagement among individuals with schizophrenia. A
comprehensive literature review revealed that up to one third of those with schizophrenia
discontinue treatment prematurely (Kreyenbuhl et al., 2009), a rate substantially higher than the
range reported by Oflson et al. (2009; 15.1%-31.6%). Kreyenbuhl et al. (2009) noted that
younger age, male gender, minority group membership, and lower levels of functioning were
positively associated with treatment disengagement and that individuals with early-onset
psychosis and co-occurring SUD were particularly at risk of discontinuing care. Finally,
Kreyenbuhl et al. (2009) found that clients’ perspectives about the care they received also
impacted treatment dropout, in that individuals who felt unheard were more likely to disengage
from treatment.
A recent study showed that treatment reengagement is associated with decreased
mortality rates (Davis et al., 2012). In a large-scale study by Davis et al. (2012), VA staff
members contacted 3,306 veterans with SMI who had failed to return for follow-up visits for at
least 1 year in an attempt to reengage them in care. Of those contacted, approximately 72%
(N=2,375) resumed treatment (Davis et al., 2012). Individuals who declined to return reported
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that they did not perceive a need for care, they were dissatisfied with VA services, they faced
transportation barriers, or several of these reasons (Davis et al., 2012). Clients who restarted
treatment were almost 6 times less likely to experience early mortality than individuals who did
not return for care (Davis et al., 2012).
Few studies have examined retention rates in integrated health programs. Data collected
from 56 federally-funded PBHC programs revealed that among the 25,648 enrollees, roughly
22% (N=5,755) terminated treatment at around 7 months from program enrollment (Scharf et al.,
2013). However, the reported rate of disengagement did not include program participants who
disengaged from care immediately following preliminary enrollment interviews (Scharf et al.,
2013). Two smaller-scale studies assessing PBHC outcomes (Druss et al., 2010; Putz et al.,
2015) reported client retention rates as part of their evaluations. Among 205 CMH clients who
received care management services in Druss et al.’s (2010) PCARE study, 78% remained in
treatment at 12-month follow up; however, among those who received usual care (N=202),
69.3% were retained at 12 follow up. In Putz et al.’s (2015) evaluation of 169 CMH clients
receiving a collaborative care intervention, 86.9% (N=147) were retained at 6 months, and 70.4%
(N=119) were retained at 12 months out.
Thomas (2017) focused specifically on correlates of treatment retention among
individuals with SMI, including individuals with thought disorders (N=119) and mood disorders
(N=192), receiving integrated services in a CMH setting. Of the 359 participants included in the
study sample, approximately half (47.1%) were retained at 6 months, while only 29.2% were
retained at 12 months (Thomas, 2017). Analyses revealed that reliable access to transportation,
abstaining from substance use, and retention at 6 months were associated with 12-month
retention (Thomas, 2017). Further, individuals with thought disorders were more likely than
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individuals with mood disorders to be retained at 12 months (at 31.1% and 25.5%, respectively;
Thomas, 2017).
Lemieux et al. (2017) expanded upon the research of Thomas (2017). Clinical data from
446 PBHC program clients (148 with thought disorders and 240 with mood disorders) were
analyzed to examine predictors of treatment retention at 6 months (Lemieux et al., 2017). Results
of multivariate analyses showed that 6-month retention was associated with type of disorder,
overall health, greater number of prescribed medications, laboratory data at baseline, having a
primary care provider, reliable transportation, and living alone (Lemieux et al., 2017). Among
these latter correlates, only two predicted retention in care at 6 months (Lemieux et al., 2017).
The number of medications prescribed at baseline and having a thought disorder increased the
likelihood of retention (Odds Ratios = 1.20 and 1.99; Lemieux et al., 2017).
Summary and Implications
SMI affects 4% of the U.S. population, notably compromising the functioning and ability
of those impacted (SAMHSA, 2016). Thought disorders are especially debilitating, and people
with these conditions, such as schizophrenia, face a variety of complicated psychiatric symptoms
(APA, 2013) and also stigma (Stuart & Arboleda-Flórez, 2012). Further, individuals with
schizophrenia have higher rates of early mortality than the general population, with research
showing that approximately 60% of early deaths among individuals diagnosed with thought
disorders are preventable (Parks et al., 2006). Efforts have been made to address the health
disparities faced by individuals with SMI through federally-supported grants (Scharf et al.,
2013); however, scant research has rigorously evaluated the effectiveness of integrated programs
in CMH settings (Gerrity et al., 2014), and even fewer studies have specifically analyzed
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treatment retention and correlates of treatment continuation among integrated PBHC program
enrollees (Thomas, 2017; Lemieux et al., 2017).
Treatment engagement is critical, with a large body of research indicating that continued
contact with providers helps individuals with SMI manage their symptoms (Druss et al., 2011).
In addition, reengagement with services following a period of disengagement is associated with
considerably lower rates of premature mortality (Davis et al., 2012). Research undertaken with
diverse populations of clients with SMI indicates that treatment retention is associated with
better outcomes, in terms of symptomology and functioning (Adair et al., 2005), and health and
wellbeing (Adair et al., 2005). Studies have also shown that certain sociodemographic (e.g.,
employment status; Olfson et al., 2009), psychosocial (e.g., higher levels of functioning;
Kreyenbuhl et al., 2009), health (e.g., abstinence from substance use; Kreyenbuhl et al., 2009),
and treatment-related characteristics (e.g., access to transportation; Davis et al., 2012) are
associated with retention among clients with SMI. However, only 2 studies specifically
examined correlates of treatment retention among CMH clients in integrated health programs.
Thomas (2017) found that the strongest predictor of treatment retention at 12 months was
retention at 6 months. Further, individuals with thought disorders were more likely than those
with mood disorders to be retained at 12 months, at 31.1% and 25.5%, respectively (Thomas,
2017). Lemieux at al. (2017) used a multivariate approach to extend the work of Thomas (2017)
and found that among the 7 correlates of treatment retention, 2 health-related characteristics
predicted 6-month retention. Individuals with thought disorders were almost twice as likely as
those with mood disorders to be retained in care at 6 months (Lemieux et al., 2017). Frequency
of medications also slightly increased the likelihood of 6-month retention (Lemieux et al., 2017).
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The few longitudinal evaluations of integrated PBHC programs indicate that CMH clients
who are retained in care show improvements on critical biomarkers of health and other measures
of psychosocial functioning and wellbeing (Druss et al., 2010; Putz et al., 2015). However, prior
to this analysis, no study to date had examined the extent to which CMH clients diagnosed with
thought disorders in integrated PBHC programs showed improvement on critical health and
psychosocial outcomes. As systems of care move toward greater integration (Gerrity et al.,
2014), evaluators are better positioned to include objective biomarkers of health, consistent with
recommendations by Parks et al. (2006; 2008), and empirically-supported psychosocial measures
when examining outcomes among individuals with SMI. The current study sought to identify and
describe health and psychosocial improvements among individuals with thought disorders
receiving integrated services in CMH settings, as well as identify the sociodemographic, healthrelated, and treatment-related characteristics that are associated with improvement. This study
also sought to increase existing knowledge about persons with thought disorders receiving
integrated PBHC services by examining relevant correlates (i.e., sociodemographic, health,
health-risk, treatment-related) of improvements in health and psychosocial characteristics.
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CHAPTER 3: CONCEPTUAL FRAMEWORK
This section outlines the purpose of the current study, the research questions that were
investigated, and definitions of relevant key terms.
Purpose
The current study is an exploratory secondary analysis that is longitudinal in scope, as
outcome measures were re-administered to particular participants at a later time (6 months;
Caruana, Roman, Hernández-Sánchez, & Solli, 2015). It examined the sociodemographic, health,
health-risk, and treatment-related characteristics that are associated with health and psychosocial
improvements among individuals with thought disorders. The present study used preexisting data
collected at baseline and follow up from clients enrolled in integrated PBHC programs at three
CMH centers in Louisiana. The data include information collected from surveys and objective
health-indicator scores recorded in clinical records.
Research Questions
The current correlational study focused on the following questions:
1. What are the sociodemographic, health, health-risk, treatment-related characteristics of
individuals with thought disorders receiving integrated PBHC in CMH settings?
2. What proportion of participants with thought disorders is retained at 6 months out?
3. Do participants with thought disorders show improvement from baseline to 6 months out
on relevant health and psychosocial characteristics?
4. Are sociodemographic, health, health-risk, and treatment-related factors associated with
improvements in psychosocial characteristics from baseline to 6 months out?
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5. Are sociodemographic, relevant health, health-risk, and treatment-related characteristics
associated with clinically meaningful improvements on objective measures of health from
baseline to 6 months out?
Key Terms
This section defines key terms included in the research questions. Chapter 4 focuses on
methodology and describes, in detail, how each variable was measured.
Sociodemographic Characteristics
Sociodemographic characteristics for the current study include age, gender, race,
employment status, disability status, living arrangement, and education level. All of the
aforementioned characteristics were self-reported by participants at baseline. Participants
reported their age, gender, and race to nurse care managers upon enrollment. Employment status
includes two categories, employed and unemployed. Employed participants reported working
either full time or part time. Unemployed participants reported that they were looking for work,
volunteering, retired, or not looking for work. Disability status refers to whether a participant
was receiving disability benefits. Living arrangement is defined as whether participants lived in
their own house or apartment or lived with someone else 30 days prior to enrollment. Finally,
education level is defined as whether a participant had less than a high school education or a high
school education or greater.
Health Characteristics
Health characteristics for the current study include the total number of prescribed
medications, whether or not antipsychotic medications were prescribed at baseline, and selfassessed health. Prescribed medications include the frequency and type of all medications
prescribed to participants that were recorded by nurse care managers at baseline, including those
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for both mental disorders and comorbid conditions. Self-assessed health is participants’ selfreported perceptions of physical health, as measured with a general self-rated health (GSRH)
question. Health-risk characteristics include participants’ self-reported use of alcohol, tobacco,
and illicit or non-prescribed drugs, as well as self-reports indicating whether participants had
ever been diagnosed with hypertension, diabetes, and heart disease.
Treatment-Related Characteristics
Treatment-related characteristics include access to reliable transportation, the number of
clinic services received, whether participants had a primary health care provider at baseline, and
clinic site. Reliable transportation reflects participants’ self-reports of having access to reliable
transportation. Number of clinic services is defined as the total number of health and mental
health services (e.g., case management, treatment planning, primary care) received by
participants, as recorded by nurse care managers. Primary health care provider at baseline refers
to whether participants reported the name of a primary care physician at baseline, as recorded by
nurse care managers. Finally, clinic site refers to 1 of 3 CMH sites where participants were
receiving integrated PBHC services.
Improvement in Psychosocial Characteristics
Psychosocial characteristics include level of functioning, level of social support, and
severity of symptomology. Level of functioning is participants’ self-reported perceptions of their
day-to-day functioning, as measured with the 8-item Perception of Functioning (PF) scale. Level
of social support reflects participants’ self-reported perceptions of social connectedness, which is
measured with a 4-item Perception of Social Connectedness (PSC) scale. Finally, severity of
symptomology is defined as participants’ self-reported feelings (e.g., nervous, hopeless, restless,
depressed, worthless) during the 30 days prior to baseline and is assessed with the 6-item K6, a
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measure of psychological distress. Improvement in psychosocial characteristics is defined as
increases in both PF and PSC scale scores and a decrease in K6 scale scores.
Improvement in Health
Clinically-meaningful improvement in health is defined as moving out of risk, as defined
by Center for Integrated Health Solutions (CIHS, 2013) guidelines, on any one of the mechanical
(i.e., systolic and diastolic BP, BMI) biomarkers of health using scores recorded in participants’
clinical records at intake and at 6 months out.
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CHAPTER 4: METHODOLOGY
This section describes the study sample, the original study from which the data were
drawn, how study variables were measured, and data analysis methods.
Design and Study Sample
This exploratory secondary analysis examined existing data collected from participants
with thought disorders who received integrated PBHC services in three different CMH settings.
The sample includes all individuals with thought disorders and was drawn from an existing
database of 1,270 participants with SMI (Lemieux et al., 2015). Participants in the original study
were primarily low-income, uninsured, and eligible for government aid (Lemieux et al., 2015).
Original Study
In the original study (Lemieux et al., 2015), clients enrolled in three, publicly funded
CMH centers were provided care management services, similar to those described in the PCARE
study (Druss et al., 2010), from February 2012 to August 2015. Clients included those who
lacked primary care providers, had not received a physical examination during the previous year,
or presented with physical health complaints (Lemieux et al., 2015). Study participants were
systematically screened by co-located nurse care managers who collected and recorded health
information and provided primary care referrals, on-site wellness program referrals, prevention
services, and education to enrolled clients (Lemieux et al., 2015).
Nurse care managers administered the National Outcomes Measures Client-level
Measures (NOMs) survey and the Integrated Health Program Baseline Physical Health Indicators
Form (IHP-BPHIF) to program participants at the time of enrollment (Lemieux et al., 2015).
Client data were de-identified, consistent with requirements of the Health Insurance Portability
and Accountability Act, and entered by the evaluators into SPSS 21 for analysis (Lemieux et al.,
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2015). The original study was exempted from oversight by the Institutional Review Board of the
researchers’ affiliated university (Lemieux et al., 2015).
The NOMs survey collects information about demographics, psychosocial functioning,
housing, education, employment, criminal history, perception of care, and social connectedness.
This measurement tool includes the Mental Health Statistics Improvement Program (MHSIP)
scale, which was created by the National Association of State Mental Health Program Directors
Research Institute (Jerrell, 2006). The IHP-BPHIF, developed by the study’s researchers and
CMH staff members, gathers information about participants’ health insurance, physical and
mental health diagnoses, prescription medications, health indicators, health-risk behaviors,
personal and family history of medical conditions, and substance use history (Lemieux et al.,
2015).
CMH clients enrolled in the Integrated Health Program (IHP) were reassessed at 6-month
intervals until they were discharged (Lemieux et al., 2015). Nurse care managers re-administered
the NOMs and also completed the Integrated Health Program Reassessment Health Indicators
Form (IHP-RHIF) at every 6-month follow up (Lemieux et al., 2015). The latter form collects
data on referral and wellness activities, health indicators, and medication changes (Lemieux et
al., 2015).
Instrumentation
Dependent Variables
The dependent variables for the current study are improvement in health and
improvement in psychosocial characteristics at 6 months out from baseline.
Improvement in Health. Improvement in health was defined as moving from at risk to
not at risk on any one of the mechanical (i.e., systolic and diastolic BP, BMI) health indicators,
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using cut-off scores recommended CIHS (2013). Health indicators were dichotomized according
to the recommended cut-off scores and coded as 0 (not at risk) and 1 (at risk).
CIHS (2013) provided the following cut-off scores for the health indicators of interest:
1. Systolic BP ≥ 130 = at risk
2. Diastolic BP ≥ 85 = at risk
3. BMI (%) ≤ 24 = normal (not at risk)
BMI 25-29 = overweight (at risk)
BMI 30-39 = obese (at risk)
In the current study, BMI scores of 24 or lower were coded as 0 (not at risk). Scores
higher than 25 were coded as 1 (at risk).
Improvement in Psychosocial Characteristics. Improvement in psychosocial
characteristics was defined an increase in PF scale scores, an increase in PSC scale scores, and a
decrease in K6 scale scores.
Level of functioning, defined as participants’ self-reported perceptions of their day-today functioning, was measured with the 8-item PF scale on the NOMs (Schacht, 2001). The PF
measure asks participants about their coping during the 30 days prior to study enrollment. For
example, PF scale items include: “I deal effectively with daily problems,” and “I am able to deal
with crisis.” A 5-point Likert scale is used to measure participants’ responses to each of the 8
items, from strongly disagree (1) to strongly agree (5). Responses to the 8 items are summed to
compute that person’s total daily functioning score, ranging from 8 to 40. Higher scores indicate
higher levels of functioning. Lemieux et al. (2015) and Thomas (2017) reported Cronbach’s
alphas of 0.76 and 0.79, respectively, indicating satisfactory internal consistency.
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Level of social support reflects participants’ self-reported perceptions of social
connectedness, which was measured with the 4-item PSC scale on the NOMs (Schacht, 2001).
The PSC measure asks participants about their personal relationships, excluding mental health
providers, during the 30 days prior to study enrollment. PSC scale items include: “I am happy
with the friends I have,” and “I feel I belong in my community.” A 5-point Likert scale is used to
measure participants’ responses to each of the 4 items, from strongly disagree (1) to strongly
agree (5). Responses to the 4 items are summed to compute that person’s total PSC score,
ranging from 4 to 20. Higher scores indicate higher levels of perceived social support. Lemieux
et al. (2015) and Thomas (2017) reported Cronbach’s alphas of 0.81 and 0.78, respectively,
indicating adequate internal consistency.
Finally, severity of symptomology was defined as participants’ self-reported feelings
(e.g., nervous, hopeless, restless, depressed, worthless) during the 30 days prior to study
enrollment, as measured with the 6-item K6 scale (Kessler et al., 2010). A 5-point Likert scale is
used to measure participants’ responses to each of the 6 items, from not at all (0) to all of the
time (4). The K6 items are summed to compute that person’s level of psychological distress,
ranging from 0 to 30. Higher scores indicate higher levels of distress. Lemieux et al. (2015) and
Thomas (2017) reported Cronbach’s alphas of 0.88 and 0.91, respectively, indicating good
internal consistency.
Independent Variables
Sociodemographic Characteristics. Sociodemographic characteristics, collected with
the NOMs survey at baseline, included age, gender, race, employment status, disability status,
living arrangement, and education level. Age was measured in years based on participants’
responses to the age-related NOMs item. Gender information was obtained from participants
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with one self-report item and was dichotomized as male (0) and female (1). With regards to race,
participants were asked to report whether they identified as Black, White, Hispanic, Asian,
Pacific Islander, Alaska Native, or American Indian; however, given the response distribution
reported by Lemieux et al. (2015), the current study dichotomized race as White (0) and Black
(1). Employment status and disability status information was obtained from participants with one
self-report NOMs item. Employment status included two categories, employed (1) and
unemployed (0). Disability status was dichotomized as yes (1) and no (0), and coding was based
on whether or not participants marked “disabled” as a reason for unemployment on the
employment status self-report item. Regarding living arrangement, participants were asked to
report type of residence (e.g., own house or apartment, with someone else, group home) 30 days
prior to study enrollment. Responses of house or apartment ownership were coded as 1, and
responses of living with someone else were coded as 0. Finally, education level was measured
based on self-reported responses to the NOMs item inquiring about participants’ highest level of
education completed. Response options included less than 12th grade, high school diploma or
GED, vocational diploma, some college, and bachelor’s or graduate degree. Education level was
dichotomized in the study as less than a high school education (0) and high school education or
greater (1).
Health Characteristics. Health characteristics for the study included the total number of
prescribed medications, whether or not antipsychotic medications were prescribed at baseline,
and self-assessed health. Information about prescribed medications included the frequency and
type of all medications prescribed to participants that were recorded by nurse care managers at
baseline. The number of prescribed medications was tallied using medication lists recorded on
IHP-BPHIF forms by nurse care managers. Participants who were prescribed antipsychotic
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medications at baseline were coded as 1 (yes), and participants who were not were coded as 0
(no). Finally, self-assessed health was measured with the GSRH question incorporated in the
NOMs survey. This item asked: “How would you rate your overall health right now?” GSRH
response options ranged from 1 (poor) to 5 (excellent).
Health-risk characteristics included participants’ self-reported use of alcohol, tobacco,
and illicit or non-prescribed drugs at baseline, as well as self-reports indicating whether
participants had ever been diagnosed with hypertension, diabetes, and heart disease. Three selfreport items on the IHP-BPHIF assessed participants’ current use of alcohol, tobacco, and illicit
or non-prescribed drugs. Use of each of the three substances was coded as 0 (no) or 1 (yes).
Finally, three self-report items on the IHP-BPHIF asked participants whether they had ever been
diagnosed with hypertension, diabetes, and heart disease. Response options for these latter items
were dichotomized (0=no, 1=yes).
Treatment-Related Characteristics. Treatment-related characteristics included access
to reliable transportation, the number of clinic services received, whether participants had a
primary health care provider at baseline, and clinic site. Access to reliable transportation was
assessed with one IHP-BPHIF item asking participants to self-report whether they had access to
reliable transportation. Responses for access to reliable transportation were dichotomized as no
(0) and yes (1). Number of clinic services was defined as the total number of monthly health and
mental health services (e.g., case management, treatment planning, primary care) received by
participants, as recorded by nurse care managers at follow up on the NOMs 6-month
reassessment survey. Primary health care provider at baseline refers to whether or not
participants reported the name of a primary care physician at baseline, as recorded by nurse care
managers on the IHP-BPHIF. Responses for primary health care provider at baseline were
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dichotomized as yes (1) and no (0). Finally, clinic site refers to 1 of 3 CMH sites where
participants were receiving integrated PBHC services. Center for Adult Behavioral Health
(CABH), Margaret Dumas Mental Health (MDMH), and Gonzales Mental Health (GMH) were
coded as 1, 2, and 3, respectively.
Data Analysis
A power analysis was conducted to confirm that a sample size of 311 was sufficient to
detect a medium effect size (0.80), with a p value set at 0.05 (Rubin & Babbie, 1993). To
summarize data, descriptive statistics for non-parametric variables (e.g., gender, race,
employment status) are reported using frequencies and their percentages (Rubin & Babbie,
2017). Descriptive statistics for parametric variables (e.g., number of health and mental health
services, self-rated health) were computed, and the mean, standard deviation, and range are
reported (Rubin & Babbie, 2017).
Paired samples t-tests were used to determine whether participants showed improvements
from baseline to follow up on level of functioning, level of social support, and severity of
symptomology (Rubin & Babbie, 2017). Bivariate analyses were used to examine associations
between key variables of interest (i.e., sociodemographic, health, health-risk, treatment-related
characteristics) and improvements in health and psychosocial functioning at 6 months out. Chisquare tests of independence were computed to examine differences in the distribution of
responses among categorical variables (e.g., disability status, health indicators, reliable
transportation; Rubin & Babbie, 2017). Independent samples t-tests were computed to assess
whether the mean scores on measures of continuous variables (e.g., age, number of medications)
differed between those who did and did not show improvements in health and psychosocial
functioning (Rubin & Babbie, 2017).
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CHAPTER 5: RESULTS
The current study examined associations between key variables of interest (i.e.,
sociodemographic, health, health-risk, and treatment characteristics) and health and psychosocial
improvements in a sample of 311 CMH clients enrolled in integrated health programs.
Sociodemographic Characteristics
As seen in Table 1, the study sample included 157 men (51.1%) and 150 women (48.9%).
The average age of participants was 45.7 (SD=13.1, Range=18-75). Nearly three fourths of the
participants were Black (72.3%), and just over one fourth was White (27.7%). The majority was
unemployed (87.7%), and just under one half (44.3%) was receiving disability benefits (see
Table 1). A slightly greater proportion of participants reported living on their own (51.8%) than
with someone else (48.2%). As seen in Table 1, well over half of participants reported having at
least a 12th grade education (61.5%).
Table 1. Sociodemographic Characteristics (N=272-307)
M
SD
Age
45.7
13.1
Gender
Male
Female

Range
18-75

Frequency
-

Valid %
-

-

-

-

157
150

51.1
48.9

-

-

-

211
81

72.3
27.7

Employment Status
Unemployed
Employed

-

-

-

265
37

87.7
12.3

Disability Status
No Benefits
Benefits

-

-

-

170
135

55.7
44.3

Living Arrangement
With Another
Own/Rented

-

-

-

131
141

48.2
51.8

Race
Black
White

(Table 1 continued)
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M

SD

Range

Frequency

Valid %

-

-

-

117
187

38.5
61.5

Education
<12th Grade
≥ 12th Grade
Health Characteristics

Table 2 displays information about the study sample’s health characteristics. On average,
participants reported taking 4 prescription medications (SD=2.4, Range=0-12), and 87.1%
reported being prescribed an antipsychotic medication. The mean score for participants on the
measure of self-assessed health was 2.8 (SD=1.1, Range=1-5), indicating that, on average,
participants viewed their health as between good and fair.
Table 2. Health Characteristics (N=301-311)
M
Number of Meds Baseline
4.0
Antipsychotic Meds Baseline
Yes
No
Self-Assessed Health

SD
2.4

Range
0-12

Frequency
-

Valid %
-

-

-

-

271
40

87.1
12.9

2.8

1.1

1-5

-

-

Health-Risk Characteristics
Table 3 shows information about relevant health-risk characteristics. Just over three
fourths (76.6%) reported no alcohol use, and slightly over half (53.1%) reported tobacco use. A
small proportion of the study sample (12.6%) reported using illicit or non-prescribed drugs. In
terms of personal history of cardiometabolic disorders, over one half of participants reported a
personal history of hypertension (54.2%), about one fifth reported a personal history of diabetes
(20.2%), and just under one half (47.4%) reported a personal history of heart disease (see Table
3).
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Table 3. Health-Risk Characteristics (N=272-305)
M
Personal Hx: Alcohol
Yes
No
-

SD

Range

Frequency

Valid %

-

-

71
232

23.4
76.7

-

-

-

162
143

53.1
46.9

Personal Hx: Drugs
Yes
No

-

-

-

38

12.6

-

-

-

263

87.4

Personal Hx: HBP
Yes
No

-

-

-

163

54.2

-

-

-

138

45.8

Personal Hx: Diabetes
Yes
No

-

-

-

60

20.2

-

-

-

237

79.8

-

-

-

129
143

47.4
52.6

Personal Hx: Tobacco
Yes
No

Personal Hx: Heart Disease
Yes
No
Treatment-Related Characteristics

As seen in Table 4, over three fourths of participants (78.3%) had access to reliable
transportation. On average, enrollees received 1.6 clinical services each month (SD=0.9,
Range=0-4.8), and just over half (55.1%) reported that they did not have a primary care
physician at baseline. In terms of clinic site, Table 4 shows that 148 individuals were enrolled at
MDMH (47.9%), 119 were enrolled at CABH (38.5%), and 42 were enrolled at GMH (13.6%).
Table 4. Treatment-Related Characteristics (N=159-309)
M
SD
Range
Reliable Transportation
Yes
No
(Table 4 continued)
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Frequency

Valid %

173

78.3

48

21.7

M
1.6

SD
0.9

Range
0-4.8

Frequency
-

Valid %
-

Yes
No

-

-

-

127
156

44.9
55.1

MDMH
CABH
GMH

-

-

-

148
119
42

47.9
38.5
13.6

Number Clinic Services
PCP Baseline

Clinic Site

Retention
Among 311 participants, approximately half (N=152, 48.9%) was retained at 6 months.
Improvement in Psychosocial Characteristics
Paired samples t-tests were performed to determine whether participants showed
improvements from baseline to follow up on measures of functioning (K6), social support (PSC),
and symptomology (PF). As seen in Table 5, the mean follow-up K6 score (M=6.5) was
significantly lower than the mean baseline K6 score (M=8.1), indicating decreased psychological
distress. The mean PSC score increased from 15.4 (baseline) to 15.9 (follow up), and the mean
PF score increased from 25.3 (baseline) to 27.8 (follow up). Improvements in level of social
support and severity of symptomology were significant (see Table 5).
Table 5. Differences from Baseline to Follow Up on Key Psychosocial Variables
K6
PSC
PF

Baseline Score
M
SD
8.1
6.2
M
15.4

SD
2.8

M
SD
25.3
4.3
*p<.05, **p<.01, ***p<.001

Follow Up Score
M
SD
6.5
5.8

95% CI for Mean Difference
Lower
Upper
.75096
2.42364

T
3.756***

df
125

M
15.9

SD
2.4

Lower
-.90890

Upper
-.14219

T
-2.711**

df
136

M
27.8

SD
4.1

Lower
-3.20087

Upper
-1.93513

T
-8.031***

df
124
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Improvement in Health
As seen in Table 6, a smaller proportion of participants was at risk at follow up (40.7%)
than at baseline (48.2%) with regard to systolic BP. However, slightly greater proportions
showed at-risk diastolic BP and BMI scores at follow up (at 29.7% and 82.1%, respectively) than
at baseline (at 28.8% and 80.7%, respectively).
Table 6. Proportions of Participants at Risk at Baseline and Follow Up
Frequency Baseline Valid % Frequency Follow Up Valid %
Systolic BP
At Risk
149
48.2
59
40.7
Not at Risk

160

51.8

86

59.3

Diastolic BP
At Risk
Not at Risk

89
220

28.8
71.2

43
102

29.7
70.3

192
46

80.7
19.3

64
14

82.1
17.9

BMI
At Risk
Not at Risk

Factors Associated with Improvement in Psychosocial Characteristics
Chi-square tests of independence were conducted to examine proportional differences in
psychosocial functioning across key categorical sociodemographic, health, health-risk, and
treatment characteristics (see Tables 7, 8, and 9). As seen in Table 8, unemployed individuals
were significantly more likely to demonstrate improvement in functioning compared to those
who were employed, at X2 = 12.035, df = 1, p<.001. Individuals who did not receive disability
benefits were more likely than those receiving assistance to show improvement in functioning, at
X2 = 4.861, df = 1, p<.05 (see Table 8). Compared to those who lived with someone else, those
who owned or rented a home were more likely to exhibit improvement in functioning, at X2 =
4.926, df = 1, p<.05 (see Table 8). With regard to social connectedness, those who did not
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receive disability benefits were more likely than those receiving assistance to perceive higher
levels of social connectedness, at X2 = 4.145, df = 1, p<.05 (see Table 9). Finally, those with
access to reliable transportation were significantly more likely to perceive higher levels of social
connectedness than those without reliable transportation, at X2 = 11.072, df = 1, p<.001 (see
Table 9).
Table 7. Proportional Differences: Improvement in Symptomology (K6)
No Improvement
Improvement
N
Valid %
N
Valid%
Gender
Male
24
50.0
40
52.6
Female
24
50.0
36
47.4
Race
Black
30
65.2
56
76.7
White
16
34.8
17
23.2
Employment Status
Unemployed
42
89.4
63
84.0
Employed
5
10.6
12
16.0
Disability Status
No Benefits
25
52.1
39
52.0
Benefits
23
47.9
36
48.0
Living Arrangement
With Another
15
34.9
31
43.7
Own/Rented
28
65.1
40
56.3
Education
<12th Grade
18
37.5
24
32.0
≥12th Grade
30
62.5
51
68.0
Antipsychotic Meds Baseline
Yes
44
88.0
67
88.2
No
6
12.0
9
11.8
Personal Hx: Alcohol
Yes
11
22.4
16
21.3
No
38
77.6
59
78.7
Personal Hx: Tobacco
Yes
30
61.2
41
54.7
No
19
38.8
34
45.3
Personal Hx: Drugs
Yes
3
6.1
11
14.7
No
46
93.9
64
85.3
(Table 7 continued)
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p

.775
.173
.405
.993
.354
.530
.979
.883
.471
.142

No Improvement
N
Valid %

Improvement
N
Valid %

p

Personal Hx: HBP

Personal Hx: Diabetes
Yes
No
Personal Hx: Heart Disease
Yes
No
Reliable Transportation
Yes
No
PCP Baseline
Yes
No
Clinic Site
MDMH
CABH
GMH

26
24

52.0
48.0

49
26

65.3
34.7

.136

13
36

26.5
73.5

16
59

21.3
78.7

.504

4
40

9.1
90.9

9
62

12.7
87.3

.555

33
6

84.6
15.4

45
15

75.0
25.0

.253

24
20

54.5
45.5

31
40

43.7
56.3

.256

22
23
4

44.9
46.9
8.2

41
26
8

54.7
35.7
10.7

.391

Table 8. Proportional Differences: Improvement in Functioning (PF)
No Improvement
Improvement
N
Valid %
N
Valid %
Gender
Male
18
48.6
42
48.8
Female
19
51.4
44
51.2
Race
Black
22
66.7
62
74.7
White
11
33.3
21
25.3
Employment Status
Unemployed
24
66.7
78
91.8
Employed
12
33.3
7
8.2
Disability Status
No Benefits
25
67.6
39
45.9
Benefits
12
32.4
46
54.1
Living Arrangement
With Another
20
54.1
26
32.5
Own/Rented
17
45.9
54
67.5
Education
<12th Grade
11
29.7
31
36.5
th
≥12 Grade
26
70.3
54
63.5
(Table 8 continued)
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p

.985
.383
.001
.027
.026
.471

No Improvement
N
Valid %
Antipsychotic Meds Baseline
Yes
No
Personal Hx: Alcohol
Yes
No
Personal Hx: Tobacco
Yes
No
Personal Hx: Drugs
Yes
No
Personal Hx: HBP
Yes
No
Personal Hx: Diabetes
Yes
No
Personal Hx: Heart Disease
Yes
No
Reliable Transportation
Yes
No
PCP Baseline
Yes
No
Clinic Site
MDMH
CABH
GMH

Improvement
N
Valid %

p

34
4

89.5
10.5

78
9

89.7
10.3

.976

9
29

23.7
76.3

16
69

18.8
81.2

.536

22
16

57.9
42.1

42
43

49.4
50.6

.384

4
34

10.5
89.5

11
74

12.9
87.1

.705

18
18

50.0
50.0

58
29

66.7
33.3

.083

6
28

17.6
82.4

24
63

27.6
72.4

.255

3
31

8.8
91.2

9
72

11.1
88.9

.714

20
6

76.9
23.1

58
14

80.6
19.4

.694

14
17

45.2
54.8

39
43

47.6
52.4

.820

15
17
5

40.5
49.5
13.5

51
27
8

59.3
31.4
9.3

.160

Table 9. Proportional Differences: Improvement in Social Connectedness (PSC)
No Improvement
Improvement
N
Valid %
N
Valid %
Gender
Male
41
48.2
26
51.0
Female
44
51.8
25
49.0
Race
Black
56
71.8
37
74.0
White
22
28.2
13
26.0
(Table 9 continued)
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p

.757
.785

No Improvement
N
Valid %
Employment Status
Unemployed
Employed
Disability Status
No Benefits
Benefits
Living Arrangement
With Another
Own/Rented
Education
<12th Grade
≥12th Grade
Antipsychotic Meds Baseline
Yes
No
Personal Hx: Alcohol
Yes
No
Personal Hx: Tobacco
Yes
No
Personal Hx: Drugs
Yes
No
Personal Hx: HBP
Yes
No
Personal Hx: Diabetes
Yes
No
Personal Hx: Heart Disease
Yes
No
Reliable Transportation
Yes
No
PCP Baseline
Yes
No
Clinic Site
MDMH
CABH
GMH

Improvement
N
Valid %

p

74
10

88.1
11.9

41
9

82.0
18.0

.328

39
46

45.9
54.1

32
18

64.0
36.0

.042

33
48

40.7
59.3

19
26

42.2
57.8

.871

30
55

35.3
64.7

16
34

32.0
68.0

.697

79
7

91.9
8.1

43
8

84.3
15.7

.171

19
66

22.4
77.6

9
41

18.0
82.0

.547

41
44

48.2
51.8

32
18

64.0
36.0

.076

8
77

9.4
90.6

8
42

16.0
84.0

.253

53
31

63.1
36.9

28
22

56.0
44.0

.417

18
66

21.4
78.6

13
36

26.5
73.5

.502

10
70

12.5
87.5

5
41

10.9
89.1

.786

62
7

89.9
10.1

24
14

63.2
36.8

.001

40
38

51.3
48.7

19
28

40.4
59.6

.239

48
30
7

56.5
35.3
8.2

23
21
6

46.0
42.0
12.0

.474
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Independent samples t-tests were computed to assess whether the mean scores on
measures of continuous sociodemographic, health, and health-risk variables differed between
those who did and did not show improvement in psychosocial functioning (see Tables 10, 11,
and 12). No significant differences emerged between participants who did and did not
demonstrate improvement in psychosocial functioning across any of the latter characteristics.
Table 10. Mean Differences: Improvement in Symptomology (K6)
M
SD
t
Age
No Improvement
45.6
12.1
Yes Improvement
47.5
12.4
-.842
Number of Meds Baseline
No Improvement
4.2
3.1
Yes Improvement
4.4
2.5
-.413
Self-Assessed Health
No Improvement
2.9
1.1
Yes Improvement
2.6
1.1
1.072
Number Clinic Services
No Improvement
1.7
0.8
Yes Improvement
1.7
0.9
-.065
Table 11. Mean Differences: Improvement in Functioning (PF)
M
SD
t
Age
No Improvement
44.1
10.4
Yes Improvement
48.5
12.7
-1.842
Number of Meds Baseline
No Improvement
4.4
3.1
Yes Improvement
4.5
2.7
-.141
Self-Assessed Health
No Improvement
2.9
1.2
Yes Improvement
2.6
1.1
1.216
Number Clinic Services
No Improvement
1.5
0.7
Yes Improvement
1.7
1.0
-1.133
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df

p

120

.401

121

.681

120

.286

118

.948

df

p

119

.068

122

.888

119

.227

118

.260

Table 12. Mean Differences: Improvement in Social Connectedness (PSC)
M
SD
t
df
Age
No Improvement
47.8
11.5
Yes Improvement
45.8
12.7
.909
132
Number of Meds Baseline
No Improvement
4.6
2.7
Yes Improvement
4.2
2.9
.740
132
Self-Assessed Health
No Improvement
2.7
1.1
Yes Improvement
2.8
1.3
-.531
130
Number Clinic Services
No Improvement
1.6
1.0
Yes Improvement
1.7
0.9
-.433
129

p
.365
.461
.596
.666

Characteristics Associated with Improvement in Health
Chi-square tests of independence were conducted to examine proportional differences in
health across key categorical sociodemographic, health, health-risk, and treatment characteristics
(see Tables 13, 14, and 15). As seen in Table 13, individuals who lived with someone else were
significantly less likely to be at risk on systolic BP than those who owned or rented a home, at X2
= 7.371, df = 1, p<.01. Participants who received services at MDMH were more likely to have
diastolic BP scores in the normal range (59.0%) compared to participants who received care at
CABH (29.0%) and GMH (12.0%), at X2 = 14.036, df = 1, p<.001 (see Table 14). Those who
received disability benefits were significantly less likely to have at-risk BMI scores than those
who were not receiving assistance, at X2 = 4.447, df = 1, p<.05 (see Table 15). Although not
statistically significant, the proportion of Black participants who were not at risk with regard to
systolic BP (85.3%) was considerably greater than White participants (14.7%; see Table 13).
Further, a greater proportion of individuals without diabetes (81.0%) were not at risk with regard
to systolic BP compared to individuals with diabetes (19.0%).
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Table 13. Proportional Differences: Improvement in Systolic BP
No Improvement
N
Valid %
Gender
Male
16
43.2
Female
21
56.8
Race
Black
22
66.7
White
11
33.3
Employment Status
Unemployed
31
83.8
Employed
6
16.2
Disability Status
No Benefits
18
48.6
Benefits
19
51.4
Living Arrangement
With Another
8
21.6
Own/Rented
29
78.4
Education
<12th Grade
13
35.1
th
≥12 Grade
24
64.9
Antipsychotic Meds Baseline
Yes
36
94.7
No
2
5.3
Personal Hx: Alcohol
Yes
9
23.7
No
29
76.3
Personal Hx: Tobacco
Yes
18
47.4
No
20
52.6
Personal Hx: Drugs
Yes
6
15.8
No
32
84.2
Personal Hx: HBP
Yes
29
78.4
No
8
21.6
Personal Hx: Diabetes
Yes
19
33.3
No
38
66.7
Personal Hx: Heart Disease
Yes
5
15.2
No
28
84.8
(Table 13 continued)
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Improvement
N
Valid %

p

19
16

54.3
45.7

.349

29
5

85.3
14.7

.074

29
5

85.3
14.7

.861

19
15

55.9
44.1

.542

17
15

53.1
46.9

.007

7
26

21.2
78.8

.198

31
4

88.6
11.4

.338

10
25

28.6
71.4

.634

15
20

42.9
57.1

.699

6
29

17.1
82.9

.876

26
9

74.3
25.7

.683

16
68

19.0
81.0

.054

6
28

17.6
82.4

.783

No Improvement
N
Valid %
Reliable Transportation
Yes
No
PCP Baseline
Yes
No
Clinic Site
MDMH
CABH
GMH

Improvement
N
Valid %

p

22
8

73.3
26.7

21
6

77.8
22.2

.697

19
16

54.3
45.7

15
18

45.5
54.5

.467

27
20
11

46.6
34.5
19.0

43
34
8

50.6
40.0
9.4

.251

Table 14. Proportional Differences: Improvement in Diastolic BP
No Improvement
N
Valid %
Gender
Male
9
39.1
Female
14
60.9
Race
Black
17
73.9
White
6
26.1
Employment Status
Unemployed
19
82.6
Employed
4
17.4
Disability Status
No Benefits
13
56.5
Benefits
10
43.5
Living Arrangement
With Another
11
50.0
Own/Rented
11
50.0
Education
<12th Grade
9
40.9
≥12th Grade
13
59.1
Antipsychotic Meds Baseline
Yes
19
82.6
No
4
17.4
Personal Hx: Alcohol
Yes
8
34.8
No
15
65.2
Personal Hx: Tobacco
Yes
12
52.2
No
11
47.8
(Table 14 continued)
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Improvement
N
Valid %

p

8
8

50.0
50.0

.501

10
3

76.9
32.1

.841

14
1

93.3
6.7

.339

7
8

46.7
53.3

.552

4
10

28.6
71.4

.204

5
10

33.3
66.7

.641

15
2

88.2
11.8

.622

6
11

35.3
64.7

.973

10
7

58.8
41.2

.676

No Improvement
N
Valid %
Personal Hx: Drugs
Yes
No
Personal Hx: HBP
Yes
No
Personal Hx: Diabetes
Yes
No
Personal Hx: Heart Disease
Yes
No
Reliable Transportation
Yes
No
PCP Baseline
Yes
No
Clinic Site
MDMH
CABH
GMH

Improvement
N
Valid %

p

7
16

30.4
69.6

4
13

23.5
76.5

.629

18
4

81.8
18.2

16
1

94.1
5.9

.255

8
15

34.8
65.2

6
10

37.5
62.5

.862

4
19

17.4
82.6

3
12

20.0
80.0

.839

13
6

68.4
31.6

12
4

75.0
25.0

.668

11
8

57.9
42.1

9
4

69.2
30.8

.515

11
25
7

25.6
58.1
16.3

59
29
12

59.0
29.0
12.0

.001

Table 15. Proportional Differences: Improvement in BMI
No Improvement
N
Valid %
Gender
Male
49
44.1
Female
62
55.9
Race
Black
78
73.6
White
28
26.4
Employment Status
Unemployed
90
82.6
Employed
19
17.4
Disability Status
No Benefits
59
53.6
Benefits
51
46.4
Living Arrangement
With Another
40
38.1
Own/Rented
65
61.9
(Table 15 continued)
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Improvement
N
Valid %

p

3
1

75.0
25.0

.223

2
2

50.0
50.0

.298

4
0

100.0
0.0

.360

0
4

0.0
100.0

.035

1
2

33.3
66.7

.867

No Improvement
N
Valid %
Education
<12th Grade
≥12th Grade
Antipsychotic Meds Baseline
Yes
No
Personal Hx: Alcohol
Yes
No
Personal Hx: Tobacco
Yes
No
Personal Hx: Drugs
Yes
No
Personal Hx: HBP
Yes
No
Personal Hx: Diabetes
Yes
No
Personal Hx: Heart Disease
Yes
No
Reliable Transportation
Yes
No
PCP Baseline
Yes
No
Clinic Site
MDMH
CABH
GMH

Improvement
N
Valid %

p

38
70

35.2
64.8

1
3

25.0
75.0

.675

101
12

89.4
10.6

4
0

100.0
0.0

.491

27
85

24.1
75.9

1
3

25.0
75.0

.967

57
55

50.9
49.1

1
3

25.0
75.0

.309

13
99

11.6
88.4

1
3

25.0
75.0

.419

71
40

64.0
36.0

3
1

75.0
25.0

.651

32
78

29.1
70.9

0
4

0.0
100.0

.203

11
92

10.7
89.3

1
3

25.0
75.0

.373

69
14

83.1
16.9

4
0

100.0
0.0

.370

56
44

56.0
44.0

2
1

66.7
33.3

.714

20
30
14

31.3
46.9
21.9

6
5
3

42.9
35.7
21.4

.676

Independent samples t-tests were computed to assess whether the mean scores on
measures of continuous sociodemographic, health, and health-risk variables differed between
those who did and did not show improvement in health (see Tables 16, 17, and 18). No
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significant differences emerged between participants who did and did not demonstrate
improvement in health across any of the latter characteristics.
Table 16. Mean Differences: Improvement in Systolic BP
M
SD
t
Age
At Risk
48.3
11.3
Not at Risk
50.1
9.5
-.732
Number of Meds Baseline
At Risk
4.5
2.9
Not at Risk
4.4
2.7
-.129
Self-Assessed Health
At Risk
2.6
1.1
Not at Risk
2.9
1.1
1.196
Number Clinic Services
At Risk
1.5
0.9
Not at Risk
1.7
0.9
1.649

df

p

70

.467

70

.898

70

.236

137

.101

df

p

37

.217

37

.124

35

.898

147

.175

t

df

p

1.294

112

.198

.307

114

.759

Table 17. Mean Differences: Improvement in Diastolic BP
M
SD
t
Age
At Risk
44.8
11.7
Not at Risk
49.3
10.1
1.255
Number of Meds Baseline
At Risk
3.3
1.8
Not at Risk
4.3
2.1
1.575
Self-Assessed Health
At Risk
2.5
1.1
Not at Risk
2.4
1.2
-.129
Number Clinic Services
At Risk
1.5
0.8
Not at Risk
1.7
1.0
1.363
Table 18. Mean Differences: Improvement in BMI
M
SD
Age
At Risk
46.8
12.2
Not at Risk
54.8
4.5
Number of Meds Baseline
At Risk
4.6
2.8
Not at Risk
5.0
3.6
(Table 18 continued)
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Self-Assessed Health
At Risk
Not at Risk
Number Clinic Services
At Risk
Not at Risk

M

SD

t

df

p

2.8
3.3

1.1
1.3

.873

112

.384

1.7
1.6

1.1
1.0

-.338

72

.736
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CHAPTER 6: DISCUSSION
The current study examined correlates (i.e., sociodemographic, health, health-risk, and
treatment-related characteristics) of health and psychosocial improvements among individuals
with thought disorders receiving integrated PBHC services in 3 CMH settings. Prior to this
analysis, no longitudinal study to date had examined correlates of improvement on critical health
and psychosocial outcomes among CMH clients diagnosed with thought disorders in integrated
PBHC programs.
Sociodemographic, Health, Health-Risk, and Treatment-Related Characteristics
As with the community-based PCARE trial (Druss et al., 2010), African-American
participants were overrepresented in the current study (72.3%). This latter finding is consistent
with extant research demonstrating that African Americans are disproportionately diagnosed
with schizophrenia (Barnes, 2008, 2013). Participants in the present study represented a
relatively disadvantaged group of individuals with thought disorders. Although over half had a
high school education or greater (61.5%), the vast majority (87.7%) was unemployed. In
addition, a slightly greater portion of IHP enrollees (44.3%) was receiving disability benefits
than PCARE enrollees (39.3%).
The prevalence of comorbid health conditions among participants in the current study is
similar to that reported in the few existing studies that have sampled CMH clients. For example,
about half of participants with thought disorders in both the current study and the national
cardiometabolic screening program study (Correll et al., 2010) had hypertension (at 54.2% and
51.0%, respectively). These rates of high BP are slightly greater than those reported by Druss et
al. (2010) in the PCARE study (at 45.5%). Rates of self-reported diabetes were also slightly
higher in the current study (20.2%) than in the PCARE study (Druss et al., 2010; 17.9%). Nearly
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half of participants in the current study (47.4%) reported comorbid cardiovascular disease,
consistent with research showing disproportionate prevalence of cardiac disease among clients in
CMH agencies (Parks et al., 2006).
The prevalence of co-occurring tobacco, alcohol, and other substance use was much
lower than that reported by Hartz et al. (2014). Just over half of the current study sample were
daily smokers; this prevalence is markedly less than the rates of smoking reported in Hartz et
al.’s (2014) large-scale epidemiological study of patients with thought disorders (at 73.4%).
Rates of self-reported alcohol use (23.4%) were also considerably lower than those described by
Hartz et al. (2014; 28.3%). Use of illicit substances was reported by 12.6% of participants in the
current study, also a lower rate than that reported by Hartz et al. (2014; 39.4%). The differences
in reported rates of health-risk behaviors may be explained by underreporting in the current
study. First, objective measures (e.g., urinalysis testing) were not utilized to confirm selfreported use of substances, which was recommended by Thomas (2017). In addition, participants
may have been reluctant to disclose actual amounts because of social desirability bias (Rubin &
Babbie, 2017).
Factors Associated with Improvement in Psychosocial Characteristics
One major objective of the current study was to examine correlates of certain
psychosocial characteristics among individuals with thought disorders. Participants in the current
descriptive study showed improvement in level of functioning and level of social support at 6
months out. With regard to sociodemographic characteristics, employment status, disability
status, and living arrangements were significantly associated with improvement in level of
functioning at 6 months out. Individuals who were unemployed at baseline were more likely to
demonstrate improvement in level of functioning at follow up than those who were employed.
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This latter finding seems counterintuitive because existing research has shown positive
correlations between employment and social functioning, symptom severity, and quality of life
among individuals with thought disorders (e.g., Marwaha & Johnson, 2004). It is possible that
individuals who were employed full time or part time upon study enrollment may have exhibited
better functioning prior to enrolling in the program. Conversely, unemployed individuals,
potentially lower functioning at baseline, may have experienced greater gains upon receiving
integrated PBHC services. It is also possible that employed participants were not able to avail
themselves of a sufficient amount of services because of scheduling constraints. Thus, additional
research is needed to understand the relationship between participants’ employment status and its
relationship to service utilization and client outcomes, including level of functioning.
Individuals who did not receive disability benefits demonstrated greater improvement in
level of functioning at 6 months out. It is likely that participants who were not receiving benefits
upon IHP enrollment were much higher functioning than those who qualified for benefits
because of more severe symptomology. Compared to those who lived with someone else,
individuals who owned or rented a home were more likely to exhibit improvement in level of
functioning at follow up. Existing studies have yielded conflicting results with regard to living
arrangement. Salokangas (1997) conducted a longitudinal study of 227 first-contact
schizophrenia patients and found that those living with family members exhibited better
functional outcomes than those not living with their families. However, Hansson et al. (2002)
found that people with schizophrenia who lived independently (N=251) had a better quality of
life and higher levels of perceived independence than those living with family members (N=78).
It is possible that participants in the current study who owned or rented their own home had the
ability to live independently, which suggests that they were higher functioning at baseline. Those

68

who lived with others may have either needed assistance or were caring for others who needed
assistance, which compromised their day-to-day functioning. However, information about
activities of daily living and caregiving responsibilities was not collected in the present study.
The association between a particular living arrangement and level of functioning is decidedly
complex and warrants further exploration in future studies. Finally, individuals who did not
receive disability benefits were more likely to perceive higher levels of social connectedness
than those who did. A reason for this finding could be that participants who were not receiving
benefits may have relied on family and kinship networks for material (e.g., transportation) and
emotional support (McFarlane, Dixon, Lukens, & Lucksted, 2003), which subsequently
influenced their perception of social connectedness. From this perspective, those who were not
receiving benefits may have had more robust social support systems out of necessity.
Conversely, participants who were receiving disability benefits may have relied on more formal
sources of support. The current study did not measure specific activities of daily living. Thus,
additional conceptualization of key variables is needed to shed light on the complex
interrelationships among sociodemographic and psychosocial characteristics of persons with
thought disorders receiving integrated PBHC services.
Individuals with access to reliable transportation were significantly more likely to
perceive higher levels of social connectedness. Palmer et al. (2002) conducted a study with 83
middle-aged and older-adult outpatients with schizophrenia and found that those who drove
(43.4%) exhibited better functional capacity. It is possible that participants with reliable
transportation had easier access to organizations and agencies that offer informal sources of
recovery and other supports (e.g., IHP wellness programs, self-help groups, adult day care
programs, church groups), thereby increasing their perception of social connectedness. On the
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other hand, it is also possible that participants with less social support had fewer individuals in
their social networks to assist them with transportation.
No health or health-risk characteristics were associated with improvements on any
psychosocial characteristics. In other words, medications, health-risk behaviors, and health
conditions did not distinguish those who improved from those who did not on measures on
functioning, social connectedness, and psychological distress. These findings are inconsistent
with those published by Lemieux et al. (2015), who reported significant interrelationships among
key health and psychosocial variables. It is possible that attrition, program length, and sample
differences contributed to disparate findings.
Characteristics Associated with Improvement in Health
The second major objective of the current study was to examine correlates of
improvement in health among individuals with thought disorders. A notable proportion of IHP
participants experienced improvement in systolic BP (with at-risk rates decreasing from 48.2%
to 40.7%), consistent with Putz et al. (2015). However, unlike participants in the latter study who
demonstrated marked improvement in diastolic BP, a slightly greater proportion of IHP
participants showed at-risk diastolic BP scores at follow up (29.7%) than at baseline (28.8%).
Also inconsistent with findings by Putz et al. (2015), who reported significant decreases in
participants’ BMI scores, a slightly greater proportion of IHP participants had at-risk BMI scores
at follow up (82.1%) than at baseline (80.7%). Increases in diastolic BP and BMI scores in the
current sample may be explained by the influence of antipsychotic medications and associated
metabolic side effects (Tandon et al., 2008). Future studies should examine type of psychotropic
medication when examining correlates of improvement in this population.
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With regard to sociodemographic factors, characteristics of living arrangements and
disability status were significantly associated with improvement in certain health characteristics
at 6 months out. A significantly greater proportion of individuals who lived with someone else
experienced improvement in systolic BP, as compared to those who lived on their own. It is
possible that those who lived with someone else received medication reminders from family
members, subsequently resulting in improved systolic BP. Without additional information about
the nuances of participants’ living situations, it is difficult to interpret this latter association with
confidence. As compared to those who did not receive disability benefits, those who did receive
assistance were significantly more likely to experience improvement in BMI from baseline to
follow up. It is possible that those with benefits were afforded greater continuity of IHP
programs, resulting in a reduction in BMI; however, such speculation would need to be
confirmed with additional data about service utilization.
Although not statistically significant, the proportion of Black participants who showed
improvement on systolic BP was substantially greater than that of White participants. It is
plausible that a greater proportion of Blacks than Whites were at risk on systolic BP at baseline,
and the improvement could reflect adherence to prescribed BP medications. The design of the
current study does not allow definitive conclusions to be drawn. Not significantly but in a
clinically meaningful fashion, a notably greater proportion of individuals who reported that they
did not have diabetes at baseline showed improvement from baseline to follow up on systolic BP,
as compared to those who did report having diabetes at baseline. It is likely that participants
without diabetes at baseline had fewer complications and cardiometabolic conditions (Parks et
al., 2006). Conversely, those with diabetes may have faced additional risks. For example, Gough
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(2005) showed that individuals with comorbid thought disorders and diabetes faced a variety of
health challenges, hampering progress in treatment.
With regard to treatment-related characteristics, clinic site was significantly associated
with improvement in health at follow up. Individuals who received IHP services at MDMH were
more likely to experience improvement in diastolic BP than participants who received services at
CABH and GMH. Anecdotal reports from MDMH staff suggest that the client population was
more stable and experienced greater continuity of treatment (C. Lemieux, personal
communication, November 27, 2017). Although not assessed in the current study, it is plausible
that clinic characteristics influence treatment continuity and subsequent improvements in health.
The current study did not examine site differences. Thus, additional research is needed to
examine the influence of provider and clinic characteristics on participants’ health outcomes.
None of the health and health-risk characteristics were associated with improvement in
objective indicators of health. This means that number of prescribed medications, whether or not
antipsychotic medications were prescribed at baseline, self-assessed health, and self-reported
history of substance use and cardiometabolic conditions did not distinguish those who
experienced improvements on objective measures of health from those who did not. These
findings are also inconsistent with those reported by Lemieux et al. (2015), who reported
significant interrelationships among key health-related factors and health outcomes. As
mentioned previously, differences may be explained by attrition, program length, and sample
differences.
Conclusions
Key findings in the current study highlight the relevance of certain sociodemographic
(i.e., employment status, disability status, living arrangement) and treatment-related (i.e., reliable
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transportation, clinic site) characteristics to health and psychosocial improvements in a sample of
CMH clients enrolled in co-located PBHC programs. No health or health-risk characteristics
were significantly associated with improvement at 6 months out. Additional concluding
observations can be made regarding study limitations, study strengths, future research, and
implications for the social work field.
Limitations and Strengths
As with all longitudinal studies, it is important to consider the methodological limitations
that may have impacted study results. Firstly, the current study is correlational in design, so
causality cannot be inferred. Data were collected from 3 CMH settings in one geographical area,
limiting generalizability of the findings to other co-located PBHC programs. The sample size
(N=311) is also a weakness, as smaller samples increase the likelihood of Type II errors
(Hackshaw, 2008). Further, attrition resulted in a notable amount of missing data on several
study variables, decreasing the number of paired cases in correlational analyses (Rubin &
Babbie, 2017). Larger confirmatory studies should be conducted in attempts to replicate the
findings of the present study. Future studies should employ random stratification sampling, and
data should be collected from multiple sites to increase representativeness. Future analyses
should also include additional longitudinal data, as 6 months may have been insufficient for
participants to show improvements. Measurement may be a problematic issue, as self-report
items introduce potential problems with reliability and validity. For example, individuals may
have underreported certain self-report items (e.g., use of illicit substances) because of social
desirability bias (Rubin & Babbie, 2017). Also related to measurement, there may have been data
entry errors, subsequently resulting in inaccuracies. Finally, the current study utilized secondary
data, limiting the number of potential research questions and study variables. There may be
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relevant correlates of psychosocial and health improvements that were not measured in the
original study. For example, studies have found that religiosity and spirituality are associated
with a number of variables that are relevant to health, such as level of psychopathology, social
integration, suicide risk, and substance use (Grover, Davuluri, & Chakrabarti, 2014). Religiosity
has also been associated with treatment compliance (Grover et al., 2014). Given the
overrepresentation of African Americans in the current study, along with a substantial corpus of
research underscoring the importance of religious belief and spirituality among African
Americans (Sanchez, Chapa, Ybarra, & Martinez, 2012), future research should incorporate
measures of these latter concepts when examining health and wellbeing.
Despite its limitations, the current study contributes to the growing knowledge base on
integrated PBHC programs and the clients who receive these services. It is the first known
longitudinal study to examine correlates of improvements in health and psychosocial
characteristics among individuals with thought disorders receiving integrated PBHC services in
CMH settings. The few published studies that sampled CMH clients receiving co-located
services focused exclusively on program outcomes (Druss et al., 2010; Putz et al., 2015) and
descriptive information (Lemieux et al., 2015), not the variables that may predict improvement.
Results from the current study showed that non health-related factors emerged as significant
correlates of improvement among individuals with thought disorders, suggesting that social
determinants are relevant for this population. No health or health-risk characteristics were
significantly associated with improvement. These findings are counterintuitive, as existing
studies (Lemieux et al., 2015) suggest the importance of both psychosocial and health-related
characteristics when considering whole-person health.
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Implications for Social Work Research
Research focused on recipients of co-located PBHC services is scant and remains a
worthy pursuit. The current study examined associations among sociodemographic and
treatment-related characteristics and improvements in health and psychosocial characteristics.
Future studies should attempt to replicate these findings with larger samples (Hackshaw, 2008),
and data should be collected from multiple sites in different geographical areas. Further, future
analyses should implement stratified sampling methods to increase representativeness.
Researchers should design studies that collect objective data (Thomas, 2017) in order to confirm
participant self-reports, and these analyses should gather additional longitudinal data in order to
allow more time for improvement. Future research should include potentially influential
variables that may predict improvement, such as religion and spirituality (Grover et al., 2014),
caregiving responsibilities, and peer support (Lemieux et al., 2015). Finally, future studies
should attempt to collect follow-up data from all participants, even those who do not return for
services, in order to better understand differences between those who do and do not show
improvement.
Implications for Social Work Practice
The current study highlights the relevance of social determinants of health among
individuals with thought disorders. Social workers should ask clients questions about their
material (e.g., transportation and disability benefits) and emotional (e.g., family and peers)
resources as part of a comprehensive assessment. Practitioners should also conduct regular
follow-up assessments to capture changes in these resources. The present study also highlights
the longstanding health disparities faced by individuals with thought disorders and the
cumulative effects of inadequate access to health care. In attempts to eliminate these disparities,
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social workers should use plain language when discussing health concerns with clients and also
help to coordinate care when clients need specialty services (Druss et al., 2010). Further, social
workers should adopt educational roles in CMH settings, teaching other providers about CMH
clients’ unique needs. Finally, many participants in the current study did not return for services at
follow up, so social workers should work towards improving treatment adherence and
appointment attendance, both of which are significantly associated with health and psychosocial
improvements (Adair et al., 2005; Druss & Walker, 2011). This might involve helping clients
secure access to reliable transportation when needed.
Implications for Social Work Education
Training and education are necessary to enhance competencies among social workers
who serve CMH clients receiving integrated PBHC services. Schools of social work should
expand existing curricula to prepare graduates for practice in integrated health settings. For
example, faculty may introduce core competencies for behavioral health and primary care (see,
e.g., Hoge, Morris, Laraia, Pomerantz, & Farley, 2014) in practice and diagnostic courses.
Diversity classes should highlight the overlapping and interdependent systems of discrimination
and disadvantage experienced by CMH clients in order to increase cultural competency and
understanding of the unique needs of individuals with SMI. Additionally, social work students
should have the opportunity to apply new knowledge in the field, subsequently improving their
ability to function professionally in integrated settings. Finally, it is critical that social workers
engage in continuing education in order to learn the latest knowledge about clients with SMI and
comorbid conditions and best practice in integrated settings.
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